<SEC-DOCUMENT>0001493152-23-004330.txt : 20230210
<SEC-HEADER>0001493152-23-004330.hdr.sgml : 20230210
<ACCEPTANCE-DATETIME>20230210171158
ACCESSION NUMBER:		0001493152-23-004330
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20230209
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230210
DATE AS OF CHANGE:		20230210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LifeMD, Inc.
		CENTRAL INDEX KEY:			0000948320
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		IRS NUMBER:				760238453
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39785
		FILM NUMBER:		23613350

	BUSINESS ADDRESS:	
		STREET 1:		236 FIFTH AVENUE
		STREET 2:		SUITE 400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		(866) 351-5907

	MAIL ADDRESS:	
		STREET 1:		236 FIFTH AVENUE
		STREET 2:		SUITE 400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CONVERSION LABS, INC.
		DATE OF NAME CHANGE:	20180622

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immudyne, Inc.
		DATE OF NAME CHANGE:	20120514

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUDYNE INC
		DATE OF NAME CHANGE:	19950720
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:LFMD="http://lifemd.com/20230209">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_LFMD_lifemd.com_20230209 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20230209_20230209 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0000948320 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityCentralIndexKey">0000948320</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lfmd-20230209.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-02-09to2023-02-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue0.01PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-092023-02-09_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20230209__20230209_zsiag2tYkFX8"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20230209__20230209_z3RF9PAU4Ug9"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 9, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20230209__20230209_zck4buI6QsCf"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityRegistrantName">LIFEMD,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20230209__20230209_z4R9AKQ0wA7d"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20230209__20230209_zbipaumXQIt2"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityFileNumber">001-39785</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20230209__20230209_zhD5z4AdDhs2"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityTaxIdentificationNumber">76-0238453</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction <br />
    of incorporation)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission
    <br />
    File Number)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer <br />
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230209__20230209_zS9DYzdWWxFh"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityAddressAddressLine1">236
Fifth Avenue</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20230209__20230209_z6ycMmmSvk49"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityAddressAddressLine2">Suite 400</ix:nonNumeric></span><br />
<span id="xdx_900_edei--EntityAddressCityOrTown_c20230209__20230209_zGp3nnFcCiX4"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20230209__20230209_zsifIcJqnOHj"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20230209__20230209_zqGZdboCLCK"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:EntityAddressPostalZipCode">10001</ix:nonNumeric></span><br />
</span>(Address of principal executive offices, including zip code)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_908_edei--CityAreaCode_c20230209__20230209_zAAB4omb2AVk"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:CityAreaCode">(866)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20230209__20230209_zgXPuruTaZIl"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" name="dei:LocalPhoneNumber">351-5907</ix:nonNumeric></span><br />
</span>(Registrant&#8217;s telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--WrittenCommunications_c20230209__20230209_z0IIZNIoUcp9"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SolicitingMaterial_c20230209__20230209_zN6XtLQv8IZh"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20230209__20230209_ziEQtzVQVLe9"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20230209__20230209_zSNADUjmtKli"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20230209__20230209__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zsBmkyIHKgLd"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember" name="dei:Security12bTitle">Common
    Stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20230209__20230209__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_z0p6KDuAFZa8"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember" name="dei:TradingSymbol">LFMD</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span>The
    <span id="xdx_90E_edei--SecurityExchangeName_c20230209__20230209__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zdLCvUFUpgb8"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20230209__20230209__us-gaap--StatementClassOfStockAxis__custom--SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_zYrhrRo00fo2"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" name="dei:Security12bTitle">Series
    A Cumulative Perpetual Preferred Stock, $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20230209__20230209__us-gaap--StatementClassOfStockAxis__custom--SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_z87NBrPOVlK9"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" name="dei:TradingSymbol">LFMDP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span>The
    <span id="xdx_90F_edei--SecurityExchangeName_c20230209__20230209__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zYJSHuUhY9ue"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20230209__20230209_zt6z9gCjSBqf"><ix:nonNumeric contextRef="From2023-02-09to2023-02-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Appointment
of Joan LaRovere to the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 9, 2023, LifeMD, Inc. (the &#8220;Company&#8221;) appointed Dr. Joan LaRovere to the board of directors (the
&#8220;Board&#8221;) of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
LaRovere is a Co-Founder and Vice President of Virtue Foundation, founded in 2002, as a non-profit organization with Special Consultative
Status to the United Nations whose mission is healthcare, education, and empowerment initiatives. She has served as an Assistant Professor
of Pediatrics at Harvard Medical School since 2011 and as a Senior Staff Physician for Cardiac Intensive Care for Boston Children&#8217;s
Hospital since 2011. Dr. LaRovere has been a Professional Advisor to the Delta V Summer Accelerator Program of Martin Trust Center for
MIT Entrepreneurship since 2016. She has also served as an Operating Partner for iSelect Fund, a venture firm which invests in companies
addressing critical global issues, since 2021. Previously, Dr. LaRovere served as Chief of the Pediatric Intensive Care Unit for The
Royal Brompton Hospital, a part of Imperial College Medical School, from 1999 to 2011. She also served as a Consulting Physician to Bupa
Cromwell Hospital from 2000 to 2011. She currently serves on the board of directors of Virtue Foundation, the Start MIT and MIT Fuse
EIR programs of the Martin Trust Center for MIT Entrepreneurship, and as a Director of Innovation and Outcomes at Boston Children&#8217;s
Hospital. <span style="background-color: white">Dr. LaRovere holds a Bachelor of Arts in Visual and Environmental Studies from Harvard
University, a Master of Science in Genetics from the University of St. Andrews, a Doctorate of Medicine from Columbia University Vagelos
College of Physicians and Surgeons, and a Master of Business Administration from the MIT Sloan School of Management.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Party Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no related party transactions with regard to Dr. LaRovere reportable under Item 404(a) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Arrangements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. LaRovere&#8217;s appointment to the Board, the Company and Dr. LaRovere entered into a Director Agreement, whereby,
as compensation for her services as a member of the Board, Dr. LaRovere received (i) a grant of 75,000 restricted shares of the Company&#8217;s
common stock, with 37,500 restricted shares vesting immediately and 37,500 restricted shares vesting on the two-year anniversary of the
Director Agreement, pursuant to a Restricted Stock Award Agreement under the LifeMD, Inc. 2020 Equity and Incentive Plan, as amended
(the &#8220;Plan&#8221;), and (ii) a stock option to purchase 37,500 shares of the Company&#8217;s common stock, vesting on the two-year
anniversary of the Director Agreement, pursuant to a Non-Qualified Stock Option Agreement under the Plan. Additionally, Dr. LaRovere
shall be paid $6,000 per quarter, as compensation for her services as a member of the Board. Unvested restricted shares and stock options
will vest immediately in the event that Dr. LaRovere is removed as director or not asked to stand for re-election for reasons other than
for &#8220;Cause,&#8221; as defined in the Plan, or immediately prior to the closing of a &#8220;Change in Control,&#8221; as defined
in the respective award agreements. The awards may be forfeited in the event of Dr. LaRovere&#8217;s breach of certain covenants contained
in the respective award agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of and does not purport to be a complete
description of the rights and obligations of the parties to the Director Agreement, Restricted Stock Award Agreement and Non-Qualified
Stock Option Agreement, and such description is qualified in its entirety by reference to the full text of the agreements, which are
filed as Exhibits 10.1 through 10.3 and incorporated by reference into this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resignation
of Kathleen E. Walsh from the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 9, 2023, Kathleen E. Walsh voluntarily resigned from her position as a member of the Board in connection with her appointment
as the Secretary of the Executive Office of Health and Human Services for the Commonwealth of Massachusetts. Ms. Walsh did not resign
as a result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2023, the Company issued a press release announcing the appointment of Joan LaRovere. A copy of the press release is filed
as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Agreement, dated February 9, 2023 between LifeMD, Inc. and Joan LaRovere</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Award Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated February 10, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIFEMD,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    10, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric Yecies</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Yecies</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Counsel and Chief Compliance Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyFkE1uwjAQhU/AHUZRlwic9GeRHY1aVBWqKEGIrZsMrUVsR2MnLUfqLTtxCmyQalmyrZn3veeJomm0tM+qQYLdY7GCDeq2kR6hwD0Smgq5I3t5TYHPAj+U8ySND8+TMLOsQdbcz+KHiguhtVcO6xREMo/FPLnlS5rcQb6OJkM9s2avajReyQakqSEn25JCL+k4Ejby2xqrj8Fqi+SUNSnEMzGWfyARcQJvtpdflg4OVqssmkzDmkRLsl072HTOWw1PDWr2cqP0skOUKvSkJbK9yzrd8f9VjzlSi76TTU7DKAjr0tvqIGZCiJiL5ackXKN+R2JILBLOs/gLN7JgARccnHlwBkIgTuFmhELLw3QD9ko8HrK2JghySVvZdMiq/4KMqpNPKwn6QRkcr/j9AlP/nww= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
DIRECTOR AGREEMENT is made as of February 9, 2023 (the &ldquo;<U>Agreement</U>&rdquo;), by and between LifeMD, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), and Dr. Joan LaRovere, an individual with an address of [***] (the &ldquo;<U>Director</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company and the Director desire to enter with respect to the appointment of the Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Director is willing to serve the Company on the terms set forth herein and in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Position</U>. Subject to the terms and provisions of this Agreement, the Director hereby agrees to serve the Company as a member of
the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;), upon the terms and conditions hereinafter set forth, provided,
however, that the Director&rsquo;s service on the Board after the next annual stockholders&rsquo; meeting shall be subject to approval
by the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Duties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
During the Directorship Term (as defined herein), the Director shall make reasonable business efforts to attend all Board meetings, serve
on appropriate committees and subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient
times and places, attend external meetings and presentations as appropriate and convenient, and perform such duties, services, and responsibilities&mdash;and
have the authority&mdash;commensurate with such position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Director will make reasonable efforts to promote the interests of the Company. The Company recognizes that the Director (i) is or
may become a full-time executive employee of another entity, and that her responsibilities to such entity must have priority and (ii)
sits or may sit on the board of directors of other entities. Notwithstanding the same, the Director will make reasonable efforts to coordinate
her respective commitments so as to fulfill her obligations to the Company and, in any event, will fulfill her legal obligations as a
Director. Other than as set forth above, the Director will not, without prior notification to the Board, engage in any other business
activity which could reasonably be expected to materially interfere with the performance of her duties, services, and responsibilities
hereunder or which is in violation of the reasonable policies established from time to time by the Company and of which the Director
has been provided copies, provided that the foregoing shall in no way limit her activities on behalf of (i) any current or future employer
and its affiliates or (ii) the board of directors of any entities on which she currently sits or hereafter joins. At such time as the
Board receives such notification, the Board may require&mdash;upon a majority vote of the remaining Directors&mdash;the resignation of
the Director if it determines that such business activity does in fact materially interfere with the performance of the Director&rsquo;s
duties, services, and responsibilities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Equity Compensation</U>. Pursuant to the Company&rsquo;s 2020 Equity and Incentive Plan (the &ldquo;Plan&rdquo;) and any amendments
thereto, the Director shall receive, upon complete execution of this Agreement, a grant of Seventy Five Thousand (75,000) restricted
shares of the Company&rsquo;s common stock, with Thirty Seven Thousand Five Hundred (37,500) shares vesting immediately upon execution
of this Agreement; and an additional Thirty Seven Thousand Five Hundred (37,500) restricted shares vesting on the two-year anniversary
of this Agreement, so long as it has not been previously terminated by the Company. The Director shall also receive a stock option to
purchase Thirty Seven Thousand Five Hundred Thousand (37,500) shares of the Company&rsquo;s common stock with an exercise price equal
to the closing share price on the grant date (which shall be the date the Director joins the Board). The stock option shall vest on the
two-year anniversary of this Agreement and shall be governed by the Plan. The foregoing grants of restricted shares and options shall
be made on the Company&rsquo;s customary form of restricted stock award and stock option award for directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Director Fees</U>. In further consideration for the Director&rsquo;s, during the Directorship Term, the Director shall be paid $6,000
per quarter payable on the first business day of each quarter (or shortly thereafter based on the first subsequent payroll issuance that
occurs in the ordinary course of business), with the first quarterly payment made upon complete execution of this Agreement (or shortly
thereafter based on the first subsequent payroll issuance that occurs in the ordinary course of business) by wire transfer (or other
means) to the account designated by the Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Independent Contractor</U>. The Director&rsquo;s status during the Directorship Term shall be that of an independent contractor and
not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration
made or provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the
Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Expense Reimbursements</U>. During the Directorship Term, the Company shall reimburse the Director for (i) all reasonable out-of-pocket
expenses incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally applicable
policies, practices, and procedures of the Company for submission of expense reports, receipts, or similar documentation of such expenses,
and (ii) any costs associated with filings required to be made by the Director or any of the entities managed or controlled by the Director
to report beneficial ownership or the acquisition or disposition of securities of the Company. Any reimbursements for material expenses
(as compared to reasonable out-of-pocket expenses of the Director) must be approved in advance by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Directorship Term</U>. The &ldquo;<U>Directorship Term</U>&rdquo; as used in this Agreement, shall mean the period commencing on the
date hereof and terminating on the earlier of the date of the next annual stockholders meeting or the earliest of the following to occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the death of the Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the termination of the Director from her membership on the Board by the mutual agreement of the Company and the Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the removal of the Director from the Board by the majority stockholders of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
the resignation by the Director from the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Director&rsquo;s Representation and Acknowledgment</U>. The Director represents to the Company that her execution and performance
of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that she has with or to any person
or entity, including without limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement
(and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have
no recourse whatsoever against any officer, director, employee, stockholder, representative, or agent of the Company or any of their
respective affiliates with regard to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Director Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Unauthorized Disclosure</U>. The Director agrees and understands that in the Director&rsquo;s position with the Company, the Director
has been and will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited
to, technical information, business and marketing plans, strategies, customer information, other information concerning the Company&rsquo;s
products, services, promotions, development, financing, expansion plans, business policies and practices, and other forms of information
considered by the Company to be confidential and proprietary, and in the nature of trade secrets. The Director agrees that during the
Directorship Term and thereafter, the Director will keep such information confidential and will not disclose such information, either
directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the
Director shall have no such obligation to the extent such information is or becomes publicly known or generally known in the Company&rsquo;s
industry other than as a result of the Director&rsquo;s breach of her obligations hereunder and (ii) the Director may, after giving prior
notice to the Company to the extent practicable and lawful under the circumstances, disclose such information to the extent required
by applicable laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical,
or territorial restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or destroy&mdash;at
the Director&rsquo;s direction, unless the Company expresses that specific returns are material and necessary&mdash;all property, keys,
notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines,
technical data, other product or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation,
in electronic form, which has been produced by, received by, or otherwise submitted to the Director in the course or otherwise as a result
of the Director&rsquo;s position with the Company during or prior to the Directorship Term, provided that the Company shall retain such
materials and make them available to the Director if requested by him/her in connection with any litigation against the Director under
circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to
her defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.
Nothing contained herein shall be deemed to preclude or restrict the Director from making any legally required disclosures or from making
disclosures pursuant to any whistleblower or similar statutory or regulatory regime.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Non-Solicitation</U>. During the Directorship Term and for a period of one (1) year thereafter, the Director shall not interfere with
the Company&rsquo;s relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination of
the Directorship Term and/or at any time during the one year period prior to the termination of the Directorship Term, was an employee
or customer (including those reasonably expected to be a customer) of the Company or otherwise had a material business relationship with
the Company. Notably, Director has pre-existing relationships, as well as those created through the ordinary course of business, from
Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation, and others&mdash;none
of which will be deemed a violation of this provision or this Agreement now or into the future, so long as there is no malicious intent
to violate this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Non-Compete</U>. During the Directorship Term and for a period of one (1) year thereafter, without the Board&rsquo;s approval, the
Director shall not in any manner, through any person, firm, or corporation, alone or as a member of a partnership or as an officer, director,
stockholder, investor, or employee of or consultant to any other corporation or enterprise, directly engage in the business of developing,
marketing, selling, or supporting technology to or for businesses in which the Company engages in or in which the Company has an actual
intention, as evidenced by the Company&rsquo;s written business plans created during the Directorship Term, to engage in, within any
geographic area in which the Company is then conducting such business. Nothing in this Section 6 shall prohibit the Director from being
(i) a stockholder in a mutual fund or a diversified investment company or (ii) a passive owner of the outstanding stock of any class
of securities of a corporation, which is publicly traded, so long as the Director has no active participation in the business of such
corporation. Notably, Director has pre-existing relationships with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect
Fund, Virtue Foundation, and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the
future, so long as there is no malicious intent to violate this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Insider Trading</U>. The Director understands and acknowledges that the securities of the Company are publicly traded and subject
to the Securities Act of 1933 and the Securities Exchange Act of 1934. As a result, the Director agrees to: (i) refrain from trading
in securities of the Company while in possession of material nonpublic information, (ii) refrain from disclosing any material nonpublic
information to anyone except as permitted in connection with the performance of the Director&rsquo;s duties hereunder or as required
by law, and (iii) communicate to any person who, to the Director&rsquo;s knowledge, receives any material nonpublic information, that
such information is material nonpublic information and that the trading and disclosure restrictions in clause (i) above also apply to
such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Remedies</U>. The Director agrees that any breach of the terms of this Section 6 would result in irreparable injury and damage to
the Company for which the Company would have no adequate remedy at law. The Director, therefore, also agrees that in the event of said
breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach
and/or threatened breach and/or continued breach by the Director and/or any and all entities acting for and/or with the Director, without
having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity.
The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach
hereof, including, but not limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not
have entered into this Agreement had the Director not agreed to the provisions of this Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The provisions of this Section 6 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action
by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement
by the Company of the covenants and agreements of this Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Termination for Cause</U>. The Company may terminate the engagement of the Director if the Board determines&mdash;upon a majority
vote of the remaining Directors&mdash;that the Director has:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
materially breached any provision hereof or habitually neglected the duties which the Director was required to perform under any provision
of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
misappropriated funds or property of the Company or otherwise engaged in acts of dishonesty, fraud, misrepresentation, or other acts
of moral turpitude, even if not in connection with the performance of the Director&rsquo;s duties hereunder, which could reasonably be
expected to result in serious prejudice to the interests of the Company if the Director was retained as a director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
secured any personal profit not completely disclosed to and approved by the Company in connection with any transaction entered into on
behalf of or with the Company or any affiliate of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
failed to carry out and perform duties assigned to the Director in accordance with the terms hereof in a manner acceptable to the Board
after a written demand for substantial performance is delivered to the Director which identifies the manner in which the Director has
not substantially performed the Director&rsquo;s duties and provided further that the Director shall be given a reasonable opportunity
to cure such failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this section, the Director shall not be terminated for Cause without: (i) reasonable notice to the Director setting forth
the reasons for the Company&rsquo;s intention to Terminate for Cause and a reasonable opportunity to cure such situation (if capable
of cure), (ii) an opportunity for the Director, together with counsel, to be heard before the Board, and (iii) delivery to the Director
of a notice of termination from the Board of the Company, finding that, in the good faith opinion of the Board, the Director had engaged
in the conduct set forth above and specifying the particulars thereof in detail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Indemnification</U>. The Company agrees to indemnify the Director for her activities as a member of the Board as set forth in the
Director and Officer Indemnification Agreement attached hereto as <B><U>Exhibit A</U></B>. In addition, the Company shall exercise its
best efforts to increase the coverage limit of its directors&rsquo; and officers&rsquo; liability insurance policy (and not otherwise
diminish the scope or value of such coverage) based on market conditions and advice received from the Audit Committee of the Board of
Directors and shall thereafter maintain in effect such coverage with a coverage limit of at least that amount and containing not materially
less favorable provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Non-Waiver of Rights</U>. The failure to enforce at any time the provisions of this Agreement or to require at any time performance
by the other party hereto of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect
either the validity of this Agreement or any part hereof, or the right of either party hereto to enforce each and every provision in
accordance with its terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this Agreement
to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any prior or subsequent
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Notices</U>. Every notice relating to this Agreement shall be in writing and shall be given by personal delivery, overnight delivery,
registered or certified mail&mdash;all with postage prepaid and return receipt requested&mdash;or email with read receipt confirmation,
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic">If to the Company:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">LifeMD, Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">236 5th Avenue, 4th Floor</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">New York, NY 10001</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">Attn:</TD>
    <TD>Justin Schreiber, CEO</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U>justin@lifemd.com</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>and/or</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Eric H. Yecies, GC &amp; CCO</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U>eric@lifemd.com</U> or <U>legal@lifemd.com</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic">If to the Director:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Dr. Joan LaRovere</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U>[***]</U></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant
to this Section 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Binding Effect/Assignment</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger), and assigns, as applicable.
Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion
of this Agreement without the prior written consent of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Entire Agreement</U>. This Agreement (together with the other agreements referred to herein) sets forth the entire understanding of
the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Severability</U>. If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in
part, such provision or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Governing Law</U>. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance
with, the laws of the State of Delaware, without regard to its conflict of laws rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Dispute Resolution</U>. In the event of any dispute arising under or pursuant to this Agreement, the parties agree to attempt to resolve
the dispute in a commercially reasonable fashion before instituting any litigation (with the exception of emergency injunctive relief).
If the parties are unable to resolve the dispute within thirty (30) days, then the parties agree to mediate the dispute with a mutually
agreed upon mediator in New York, NY. If the parties cannot agree upon a mediator within ten (10) days after either party shall first
request commencement of mediation, each party will select a mediator within five (5) days thereof, and those mediators shall select the
mediator to be used. The mediation shall be scheduled within thirty (30) days following the selection of the mediator. The parties further
agree that any applicable statute of limitations will be tolled for the period of time from the date mediation is requested until 14
days following the mediation. If the mediation does not resolve the dispute, then the parties irrevocably and unconditionally (i) agree
that any action or proceeding arising out of or in connection with this Agreement shall be brought in the Chancery Court of the State
of Delaware (the &ldquo;<U>Delaware Court</U>&rdquo;), and not in any other state or federal court in the United States of America or
any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action
or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action
or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding
brought in the Delaware Court has been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Legal Fees</U>. The parties hereto agree that the non-prevailing party in any dispute, claim, action, or proceeding between the parties
hereto arising out of or relating to the terms and conditions of this Agreement or any provision thereof (a &ldquo;<U>Dispute</U>&rdquo;),
shall reimburse the prevailing party for reasonable attorney&rsquo;s fees and expenses incurred by the prevailing party in connection
with such Dispute; provided, however, that the Director shall only be required to reimburse the Company for its fees and expenses incurred
in connection with a Dispute if the Director&rsquo;s position in such Dispute was found by the court, arbitrator, or other person or
entity presiding over such Dispute to be frivolous or advanced not in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<U>Mutual Non-Disparagement</U>. The parties mutually agree to forbear from making, causing to be made, publishing, ratifying, or endorsing
any and all disparaging remarks, derogatory statements or comments made to any party with respect to either of them. Nothing herein shall
prohibit Director from enforcing her rights under the restricted stock award agreement and the stock option award agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<U>Modifications</U>. Neither this Agreement nor any provision hereof may be modified, altered, amended, or waived except by an instrument
in writing duly signed by the party to be charged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Tense and Headings</U>. Whenever any words used herein are in the singular form, they shall be construed as though they were also
used in the plural form in all cases where they would so apply. The headings contained herein are solely for the purposes of reference,
are not part of this Agreement and shall not in any way affect the meaning or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but
all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[-Signature
Page Follows-]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board, and the Director has hereunto
set her hand, on the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">LIFEMD, INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><I>/s/ Justin Schreiber</I></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Justin Schreiber</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">DIRECTOR</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/&nbsp;Dr. Joan LaRovere</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Dr. Joan LaRovere, an individual</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page To Director Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR
AND OFFICER INDEMNIFICATION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Director and Officer Indemnification Agreement, dated as of February 9, 2023 (the <B><I>&ldquo;Agreement&rdquo;</I></B>), is made by
and between LifeMD, Inc., a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), and Joan LaRovere (the <B><I>&ldquo;Indemnitee&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The Delaware General Corporation Law provides that the business and affairs of a corporation shall be managed by or under the direction
of its board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
By virtue of the managerial prerogatives vested in the directors and officers of a Delaware corporation, directors, and officers act
as fiduciaries of the corporation and its stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
It is critically important to the Company and its stockholders that the Company be able to attract and retain the most capable persons
reasonably available to serve as directors and officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
In recognition of the need for corporations to be able to induce capable and responsible persons to accept positions in corporate management,
Delaware law authorizes (and in some instances requires) corporations to indemnify their directors and officers, and further authorizes
corporations to purchase and maintain insurance for the benefit of their directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
Courts have recognized that indemnification by a corporation serves the dual policies of (1) allowing corporate officials to resist unjustified
lawsuits, secure in the knowledge that, if vindicated, the corporation will bear the expense of litigation, and (2) encouraging capable
women and men to serve as corporate directors and officers, secure in the knowledge that the corporation will absorb the costs of defending
their honesty and integrity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
The number of lawsuits challenging the judgment and actions of directors and officers of corporations, the costs of defending those lawsuits,
and the threat to personal assets have all materially increased over the past several years, chilling the willingness of capable women
and men to undertake the responsibilities imposed on corporate directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
Recent federal legislation and rules adopted by the Securities and Exchange Commission and the national securities exchanges have exposed
such directors and officers to new and substantially broadened civil liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.
Under Delaware law, a director&rsquo;s or officer&rsquo;s right to be reimbursed for the costs of defense of criminal actions, whether
such claims are asserted under state or federal law, does not depend upon the merits of the claims asserted against the director or officer
and is separate and distinct from any right to indemnification the director may be able to establish.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
Indemnitee is, or will be, a director of the Company and her or her willingness to serve in such capacity is predicated, in substantial
part, upon the Company&rsquo;s willingness to indemnify him or her in accordance with the principles reflected above, to the fullest
extent permitted by the laws of the State of Delaware, and upon the other undertakings set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.
In recognition of the need to provide Indemnitee with substantial protection against personal liability, in order to procure Indemnitee&rsquo;s
service as a director of the Company and to enhance Indemnitee&rsquo;s ability to serve the Company in an effective manner, and in order
to provide such protection pursuant to express contract rights (intended to be enforceable irrespective of, among other things, any amendment
to the Company&rsquo;s certificate of incorporation or bylaws (collectively, the <B><I>&ldquo;Constituent Documents&rdquo;</I></B>),
any change in the composition of the Company&rsquo;s Board of Directors (the <B><I>&ldquo;Board&rdquo;</I></B>), or any change-in-control
or business combination transaction relating to the Company), the Company wishes to provide in this Agreement for the indemnification
and advancement of Expenses (as defined herein) to Indemnitee on the terms, and subject to the conditions, set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
In light of the considerations referred to in the preceding recitals, it is the Company&rsquo;s intention and desire that the provisions
of this Agreement be construed liberally, subject to their express terms, to maximize the protections to be provided to Indemnitee hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, the parties hereto hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Certain Definitions</U>. In addition to terms defined elsewhere herein, the following terms have the following meanings when used
in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B><I>&ldquo;Change in Control&rdquo;</I></B> shall have occurred at such time, if any, as Incumbent Directors cease for any reason to
constitute a majority of the directors. For purposes of this Section 1(a), <B><I>&ldquo;Incumbent Directors&rdquo;</I></B> means the
individuals who, as of the date hereof, are directors of the Company and any individual becoming a director subsequent to the date hereof
whose election, nomination for election by the Company&rsquo;s stockholders, or appointment, was approved by a vote of at least a majority
of the then Incumbent Directors (either by a specific vote or by approval of the proxy statement of the Company in which such person
is named as a nominee for director, without objection to such nomination); provided, however, that an individual shall not be an Incumbent
Director if such individual&rsquo;s election or appointment to the Board occurs as a result of an actual or threatened election contest
(as described in Rule 14a-12(c) of the Securities Exchange Act of 1934, as amended) with respect to the election or removal of directors
or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B><I>&ldquo;Claim&rdquo;</I></B> means (i) any threatened, asserted, pending, or completed claim, demand, action, suit, or proceeding&mdash;whether
civil, criminal, administrative, arbitrative, investigative, or other, and whether made pursuant to federal, state or other law; and
(ii) any inquiry or investigation&mdash;whether made, instituted, or conducted by the Company or any other Person&mdash;including, without
limitation, any federal, state, or other governmental entity that Indemnitee reasonably determines might lead to the institution of any
such claim, demand, action, suit or proceeding. For the avoidance of doubt, the Company intends the indemnity to be provided hereunder
for acts or failure to act prior to, on, or after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B><I>&ldquo;Controlled Affiliate&rdquo;</I></B> means any corporation, limited liability company, partnership, joint venture, trust,
or other entity or enterprise, whether or not for profit, that is directly or indirectly controlled by the Company. For purposes of this
definition, <B><I>&ldquo;control&rdquo;</I></B> means the possession, directly or indirectly, of the power to direct or cause the direction
of the management or policies of an entity or enterprise, whether through the ownership of voting securities, through other voting rights,
by contract, or otherwise; provided that direct or indirect beneficial ownership of capital stock or other interests in an entity or
enterprise entitling the holder to cast 15% or more of the total number of votes generally entitled to be cast in the election of directors
(or persons performing comparable functions) of such entity or enterprise shall be deemed to constitute control for purposes of this
definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B><I>&ldquo;Disinterested Director&rdquo;</I></B> means a director of the Company who is not and was not a party to the Claim in respect
of which indemnification is sought by Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B><I>&ldquo;Expenses&rdquo;</I></B> means reasonable attorneys&rsquo; and experts&rsquo; fees and expenses, and all other costs and
expenses paid or payable in connection with investigating, defending, being a witness in, or participating in (including on appeal),
or preparing to investigate, defend, be a witness in or participate in (including on appeal), any Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B><I>&ldquo;Indemnifiable Claim&rdquo;</I></B> means any Claim based upon, arising out of or resulting from (i) any actual, alleged
or suspected act or failure to act by Indemnitee in her capacity as a director, officer, employee, or agent of the Company or as a director,
officer, employee, member, manager, trustee, or agent of any other corporation, limited liability company, partnership, joint venture,
trust, or other entity or enterprise, whether or not for profit, as to which Indemnitee is or was serving at the request of the Company,
(ii) any actual, alleged or suspected act or failure to act by Indemnitee in respect of any business, transaction, communication, filing,
disclosure or other activity of the Company or any other entity or enterprise referred to in clause (i) of this sentence, or (iii) Indemnitee&rsquo;s
status as a current or former director, officer, employee, or agent of the Company or as a current or former director, officer, employee,
member, manager, trustee, or agent of the Company or any other entity or enterprise referred to in clause (i) of this sentence or any
actual, alleged, or suspected act or failure to act by Indemnitee in connection with any obligation or restriction imposed upon Indemnitee
by reason of such status. In addition to any service at the actual request of the Company, for purposes of this Agreement, Indemnitee
shall be deemed to be serving or to have served at the request of the Company as a director, officer, employee, member, manager, trustee,
or agent of another entity or enterprise if Indemnitee is or was serving as a director, officer, employee, member, manager, agent, trustee
or other fiduciary of such entity or enterprise and (i) such entity or enterprise is, or at the time of such service was, a Controlled
Affiliate, (ii) such entity or enterprise is or at the time of such service was an employee benefit plan (or related trust) sponsored
or maintained by the Company or a Controlled Affiliate, or (iii) the Company or a Controlled Affiliate (by action of the Board, any committee
thereof or the Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;) (other than as the CEO himself)) caused or authorized Indemnitee
to be nominated, elected, appointed, designated, employed, engaged, or selected to serve in such capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B><I>&ldquo;Indemnifiable Losses&rdquo;</I></B> means any and all Losses relating to, arising out of or resulting from any Indemnifiable
Claim; provided, however, that Indemnifiable Losses shall not include Expenses incurred by Indemnitee in respect of any Indemnifiable
Claim (or any matter or issue therein) as to which Indemnitee shall have been adjudged liable to the Company (where such adjudication
must be final and non-appealable), unless and only to the extent that the court in which such Indemnifiable Claim was brought shall have
determined upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee
is fairly and reasonably entitled to indemnification for such Expenses as the court shall deem proper (<I>i.e.</I>, there was no bad
faith, gross negligence, and/or willful misconduct by the Director).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B><I>&ldquo;Independent Counsel&rdquo;</I></B> means a nationally recognized law firm, or a member of a nationally recognized law firm,
that is experienced in matters of Delaware corporate law and neither presently is, nor in the past five years has been, retained to represent:
(i) the Company (or any subsidiary) or Indemnitee in any matter material to either such party (other than with respect to matters concerning
the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii) any other named (or, as
to a threatened matter, reasonably likely to be named) party to the Indemnifiable Claim giving rise to a claim for indemnification hereunder.
Notwithstanding the foregoing, the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards
of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee&rsquo;s rights under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B><I>&ldquo;Losses&rdquo;</I></B> means any and all Expenses, damages, losses, liabilities, judgments, fines, penalties (whether civil,
criminal, or other), and amounts paid or payable in settlement, including, without limitation, all interest, assessments, and other charges
paid or payable in connection with or in respect of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B><I>&ldquo;Person&rdquo;</I></B> means any individual, entity, or group, within the meaning of Section 13(d)(3) or 14(d)(2) of the
Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B><I>&ldquo;Standard of Conduct&rdquo;</I></B> means the standard for conduct by Indemnitee that is a condition precedent to indemnification
of Indemnitee hereunder against Indemnifiable Losses relating to, arising out of, or resulting from an Indemnifiable Claim. The Standard
of Conduct is (i) good faith and a reasonable belief by Indemnitee that her action was in or not opposed to the best interests of the
Company and, with respect to any criminal action or proceeding, that Indemnitee had no reasonable cause to believe that her conduct was
unlawful, or (ii) any other applicable standard of conduct that may hereafter be substituted under the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Indemnification Obligation</U>. Subject only to Section 7 and to the proviso in this Section, the Company shall indemnify, defend
and hold harmless Indemnitee, to the fullest extent permitted by the laws of the State of Delaware in effect on the date hereof or as
such laws may from time to time hereafter be amended to increase the scope of such permitted indemnification, against any and all Indemnifiable
Claims and Indemnifiable Losses; provided, however, that, except as provided in Section 5, Indemnitee shall not be entitled to indemnification
pursuant to this Agreement in connection with (i) any Claim initiated by Indemnitee against the Company or any director or officer of
the Company unless the Company has joined in or consented to the initiation of such Claim or the Claim relates to or arises from the
enforcement or prosecution of a right to indemnification under this Agreement, or (ii) the purchase and sale by Indemnitee of securities
in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended. Nothing herein is intended to limit the scope of permitted
indemnification to Indemnitee under the laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Advancement of Expenses</U>. Indemnitee shall have the right to advancement by the Company, prior to the final disposition of any
Indemnifiable Claim, of any and all actual and reasonable Expenses relating to, arising out of, or resulting from any Indemnifiable Claim
paid or incurred by Indemnitee. Without limiting the generality or effect of any other provision hereof, Indemnitee&rsquo;s right to
such advancement is not subject to the satisfaction of any Standard of Conduct. Without limiting the generality or effect of the foregoing,
within ten business days after any request by Indemnitee that is accompanied by supporting documentation for specific reasonable Expenses
to be reimbursed or advanced, the Company shall, in accordance with such request (but without duplication), (a) pay such Expenses on
behalf of Indemnitee, (b) advance to Indemnitee funds in an amount sufficient to pay such Expenses, or (c) reimburse Indemnitee for such
Expenses; provided that Indemnitee shall repay, without interest, any amounts actually advanced to Indemnitee that, at the final disposition
of the Indemnifiable Claim to which the advance related, were in excess of amounts paid or payable by Indemnitee in respect of Expenses
relating to, arising out of or resulting from such Indemnifiable Claim. In connection with any such payment, advancement, or reimbursement,
at the request of the Company, Indemnitee shall execute and deliver to the Company an undertaking, which need not be secured and shall
be accepted without reference to Indemnitee&rsquo;s ability to repay the Expenses, by or on behalf of the Indemnitee, to repay any amounts
paid, advanced, or reimbursed by the Company in respect of Expenses relating to, arising out of, or resulting from any Indemnifiable
Claim in respect of which it shall have been determined, following the final disposition of such Indemnifiable Claim and in accordance
with <U>Section 7</U>, that Indemnitee is not entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Indemnification for Additional Expenses</U>. Without limiting the generality or effect of the foregoing, the Company shall indemnify
and hold harmless Indemnitee against and, if requested by Indemnitee, shall reimburse Indemnitee for, or advance to Indemnitee, within
ten business days of such request accompanied by supporting documentation for specific Expenses to be reimbursed or advanced, any and
all actual and reasonable Expenses paid or incurred by Indemnitee in connection with any Claim made, instituted, or conducted by Indemnitee
for (a) indemnification or reimbursement or advance payment of Expenses by the Company under any provision of this Agreement, or under
any other agreement or provision of the Constituent Documents now or hereafter in effect relating to Indemnifiable Claims, and/or (b)
recovery under any directors&rsquo; and officers&rsquo; liability insurance policies maintained by the Company; provided, however, if
it is ultimately determined that the Indemnitee is not entitled to such indemnification, reimbursement, advance or insurance recovery,
as the case may be, then the Indemnitee shall be obligated to repay any such Expenses to the Company; provided further, that, regardless
in each case of whether Indemnitee ultimately is determined to be entitled to such indemnification, reimbursement, advance, or insurance
recovery, as the case may be, Indemnitee shall return, without interest, any such advance of Expenses (or portion thereof) which remains
unspent at the final disposition of the Claim to which the advance related.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Partial Indemnity</U>. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some
or a portion of any Indemnifiable Loss but not for the entire amount thereof, the Company shall nevertheless indemnify Indemnitee for
the portion thereof to which Indemnitee is entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Procedure for Notification</U>. To obtain indemnification under this Agreement in respect of an Indemnifiable Claim or Indemnifiable
Loss, Indemnitee shall submit to the Company a written request therefore, including a brief description (based upon information then
available to Indemnitee) of such Indemnifiable Claim or Indemnifiable Loss. If, at the time of the receipt of such request, the Company
has directors&rsquo; and officers&rsquo; liability insurance in effect under which coverage for such Indemnifiable Claim or Indemnifiable
Loss is potentially available, the Company shall give prompt written notice of such Indemnifiable Claim or Indemnifiable Loss to the
applicable insurers in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all necessary
or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all Indemnifiable Claims and Indemnifiable Losses in
accordance with the terms of such policies. The Company shall provide to Indemnitee a copy of such notice delivered to the applicable
insurers, substantially concurrently with the delivery thereof by the Company. The failure by Indemnitee to timely notify the Company
of any Indemnifiable Claim or Indemnifiable Loss shall not relieve the Company from any liability hereunder unless, and only to the extent
that, the Company did not otherwise learn of such Indemnifiable Claim or Indemnifiable Loss and to the extent that such failure results
in forfeiture by the Company of substantial defenses, rights, or insurance coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Determination of Right to Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To the extent that Indemnitee shall have been successful on the merits or otherwise in defense of any Indemnifiable Claim or any portion
thereof or in defense of any issue or matter therein, including, without limitation, dismissal without prejudice, Indemnitee shall be
indemnified against all Indemnifiable Losses relating to, arising out of or resulting from such Indemnifiable Claim in accordance with
Section 2 and no Standard of Conduct Determination (as defined in Section 7(b)) shall be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent that the provisions of Section 7(a) are inapplicable to an Indemnifiable Claim that shall have been finally disposed of,
any determination required to be made under the laws of the State of Delaware as to whether Indemnitee has satisfied the applicable Standard
of Conduct (a <B><I>&ldquo;Standard of Conduct Determination&rdquo;</I></B>) shall be made as follows: (i) if a Change in Control shall
not have occurred, or if a Change in Control shall have occurred but Indemnitee shall have requested that the Standard of Conduct Determination
be made pursuant to this clause (i), (A) by a majority vote of the Disinterested Directors, even if less than a quorum of the Board,
(B) if such Disinterested Directors so direct, by a majority vote of a committee of Disinterested Directors designated by a majority
vote of all Disinterested Directors, or (C) if there are no such Disinterested Directors, or if a majority of the Disinterested Directors
so direct, by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered to Indemnitee; and
(ii) if a Change in Control shall have occurred and Indemnitee shall not have requested that the Standard of Conduct Determination be
made pursuant to clause (i) above, by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered
to Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If (i) Indemnitee shall be entitled to indemnification hereunder against any Indemnifiable Losses pursuant to Section 7(a), (ii) no determination
of whether Indemnitee has satisfied any applicable standard of conduct under Delaware law is a legally required condition precedent to
indemnification of Indemnitee hereunder against any Indemnifiable Losses, or (iii) Indemnitee has been determined or deemed pursuant
to Section 7(b) to have satisfied the applicable Standard of Conduct, then the Company shall pay to Indemnitee, within ten business days
after the later of (x) the notification date in respect of the Indemnifiable Claim or portion thereof to which such Indemnifiable Losses
are related, out of which such Indemnifiable Losses arose or from which such Indemnifiable Losses resulted, and (y) the earliest date
on which the applicable criterion specified in clause (i), (ii) or (iii) above shall have been satisfied, an amount equal to the amount
of such Indemnifiable Losses. Nothing herein is intended to mean or imply that the Company is intending to use the Delaware General Corporations
Law to dispense with a requirement that Indemnitee meet the applicable Standard of Conduct where it is otherwise required by such statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If a Standard of Conduct Determination is required to be, but has not been, made by Independent Counsel pursuant to Section 7(b)(i),
the Independent Counsel shall be selected by the Board or a committee of the Board, and the Company shall give written notice to Indemnitee
advising him or her of the identity of the Independent Counsel so selected. If a Standard of Conduct Determination is required to be,
or to have been, made by Independent Counsel pursuant to Section 7(b)(ii), the Independent Counsel shall be selected by Indemnitee, and
Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either case,
Indemnitee or the Company, as applicable, may, within ten business days after receiving written notice of selection from the other, deliver
to the other a written objection to such selection<I>; </I>provided, however, that such objection may be asserted only on the ground
that the Independent Counsel so selected does not satisfy the criteria set forth in the definition of &ldquo;Independent Counsel&rdquo;
in Section 1(h), and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely
objection, the Person so selected shall act as Independent Counsel. If such written objection is properly and timely made and substantiated,
(i) the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court
has determined that such objection is without merit and (ii) the non-objecting party may, at its option, select an alternative Independent
Counsel and give written notice to the other party advising such other party of the identity of the alternative Independent Counsel so
selected, in which case the provisions of the two immediately preceding sentences and clause (i) of this sentence shall apply to such
subsequent selection and notice. If applicable, the provisions of clause (ii) of the immediately preceding sentence shall apply to successive
alternative selections. If no Independent Counsel that is permitted under the foregoing provisions of this Section 7(d) to make the Standard
of Conduct Determination shall have been selected within 30 calendar days after the Company gives its initial notice pursuant to the
first sentence of this Section 7(d) or Indemnitee gives its initial notice pursuant to the second sentence of this Section 7(d), as the
case may be, either the Company or Indemnitee may petition the courts of the State of Delaware for resolution of any objection which
shall have been made by the Company or Indemnitee to the other&rsquo;s selection of Independent Counsel and/or for the appointment as
Independent Counsel of a person or firm selected by such court or by such other person as such Court shall designate, and the person
or firm with respect to whom all objections are so resolved or the person or firm so appointed will act as Independent Counsel. In all
events, the Company shall pay all of the actual and reasonable fees and expenses of the Independent Counsel incurred in connection with
the Independent Counsel&rsquo;s determination pursuant to Section 7(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Cooperation</U>. Indemnitee shall cooperate with reasonable requests of the Company in connection with any Indemnifiable Claim and
any individual or firm making such Standard of Conduct Determination, including providing to such Person documentation or information
which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary
to defend the Indemnifiable Claim or make any Standard of Conduct Determination without incurring any unreimbursed cost in connection
therewith. The Company shall indemnify and hold harmless Indemnitee against and, if requested by Indemnitee, shall reimburse Indemnitee
for, or advance to Indemnitee, within ten business days of such request accompanied by supporting documentation for specific costs and
expenses to be reimbursed or advanced, any and all costs and expenses (including reasonable attorneys&rsquo; and experts&rsquo; fees
and expenses) actually and reasonably incurred by Indemnitee in so cooperating with the Person defending the Indemnifiable Claim or making
such Standard of Conduct Determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Presumption of Entitlement</U>. Notwithstanding any other provision hereof, in making any Standard of Conduct Determination, the Person
making such determination shall presume that Indemnitee has satisfied the applicable Standard of Conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>No Other Presumption</U>. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement (whether with
or without court approval) or conviction, or upon a plea of nolo contendere or its equivalent, will not create a presumption that Indemnitee
did not meet any applicable Standard of Conduct or that indemnification hereunder is otherwise not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Non-Exclusivity</U>. The rights of Indemnitee hereunder will be in addition to any other rights Indemnitee may have under the Constituent
Documents, or the substantive laws of the State of Delaware, any other contract or otherwise (collectively, <B><I>&ldquo;Other Indemnity
Provisions&rdquo;</I></B>); provided, however, that (a) to the extent that Indemnitee otherwise would have any greater right to indemnification
under any Other Indemnity Provision, Indemnitee will without further action be deemed to have such greater right hereunder, and (b) to
the extent that any change is made to any Other Indemnity Provision which permits any greater right to indemnification than that provided
under this Agreement as of the date hereof, Indemnitee will be deemed to have such greater right hereunder. The Company may not, without
the consent of Indemnitee, adopt any amendment to any of the Constituent Documents the effect of which would be to deny, diminish, or
encumber Indemnitee&rsquo;s right to indemnification under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Liability Insurance and Funding</U>. For the duration of Indemnitee&rsquo;s service as a director of the Company and for a reasonable
period of time thereafter, which such period shall be determined by the Company in its sole discretion but shall in no event be less
than two (2) years, the Company shall cause to be maintained in effect policies of directors&rsquo; and officers&rsquo; liability insurance
providing coverage for directors and/or officers of the Company, that is substantially comparable in scope and amount to that provided
by the Company&rsquo;s current policies of directors&rsquo; and officers&rsquo; liability insurance. Upon reasonable request, the Company
shall provide Indemnitee or her or her counsel with a copy of all directors&rsquo; and officers&rsquo; liability insurance applications,
binders, policies, declarations, endorsements, and other related materials. In all policies of directors&rsquo; and officers&rsquo; liability
insurance obtained by the Company, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights
and benefits, subject to the same limitations, as are accorded to the Company&rsquo;s directors and officers most favorably insured by
such policy. Notwithstanding the foregoing, the Company may, but shall not be required to, create a trust fund, grant a security interest,
or use other means, including, without limitation, a letter of credit, to ensure the payment of such amounts as may be necessary to satisfy
its obligations to indemnify and advance expenses pursuant to this Agreement. The Company understands and acknowledges that the Director
may resign from all positions with the Company if it fails to timely implement, or to thereafter maintain in place, such increased coverages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Subrogation</U>. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all
of the related rights of recovery of Indemnitee against other Persons (other than Indemnitee&rsquo;s successors), including any entity
or enterprise referred to in clause (i) of the definition of &ldquo;Indemnifiable Claim&rdquo; in Section 1(f). Indemnitee shall execute
all papers reasonably required to evidence such rights (all of Indemnitee&rsquo;s reasonable Expenses, including reasonable attorneys&rsquo;
fees and charges, related thereto to be reimbursed by or, at the option of Indemnitee, advanced by the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>No Duplication of Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall not be liable under this Agreement to make any payment to Indemnitee in respect of any Indemnifiable Losses to the
extent Indemnitee has otherwise already actually received payment (net of Expenses incurred in connection therewith) under any insurance
policy, the Constituent Documents and Other Indemnity Provisions or otherwise (including from any entity or enterprise referred to in
clause (i) of the definition of &ldquo;Indemnifiable Claim&rdquo; in Section 1(f)) in respect of such Indemnifiable Losses otherwise
indemnifiable hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding anything to the contrary contained in Section 14(a) above, the Company hereby acknowledges that Indemnitee may have certain
rights to indemnification, advancement of expenses, and/or insurance provided by one or more venture capital funds, the general partners,
managing members, or other control persons and/or any affiliated management companies of such venture capital funds, and certain of its
or their affiliates (collectively, the &ldquo;<B><I>Fund Indemnitors</I></B>&rdquo;). The Company hereby agrees that in connection with
any Indemnifiable Claim, (i) it is the indemnitor of first resort (<I>i.e.</I>, its obligations to Indemnitee are primary and any obligation
of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee
are secondary), (ii) it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full
amount of all Expenses, judgments, penalties, fines, and amounts paid in settlement to the extent legally permitted and as required by
the terms of this Agreement and the Company&rsquo;s Constituent Documents (or any other agreement between the Company and Indemnitee),
without regard to any rights Indemnitee may have against the Fund Indemnitors, and, (iii) it irrevocably waives, relinquishes, and releases
the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any
kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with
respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors
shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery
of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of
the terms of this Section 14(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Defense of Claims</U>. Subject to the provisions of applicable policies of directors&rsquo; and officers&rsquo; liability insurance,
if any, the Company shall be entitled to participate in the defense of any Indemnifiable Claim or to assume or lead the defense thereof
with counsel reasonably satisfactory to the Indemnitee; provided that if Indemnitee determines, after consultation with counsel selected
by Indemnitee, that (a) the use of counsel chosen by the Company to represent Indemnitee would present such counsel with an actual or
potential conflict, (b) the named parties in any such Indemnifiable Claim (including any impleaded parties) include both the Company
and Indemnitee, and Indemnitee shall conclude that there may be one or more legal defenses available to him or her that are different
from or in addition to those available to the Company, (c) any such representation by such counsel would be precluded under the applicable
standards of professional conduct then prevailing, or (d) Indemnitee has interests in the claim or underlying subject matter that are
different from or in addition to those of other Persons against whom the Claim has been made or might reasonably be expected to be made,
then Indemnitee shall be entitled to retain separate counsel (but not more than one law firm plus, if applicable, local counsel in respect
of any particular Indemnifiable Claim for all indemnitees in Indemnitee&rsquo;s circumstances) at the Company&rsquo;s expense. The Company
shall not be liable to Indemnitee under this Agreement for any amounts paid in settlement of any threatened or pending Indemnifiable
Claim effected without the Company&rsquo;s prior written consent. The Company shall not, without the prior written consent of the Indemnitee,
effect any settlement of any threatened or pending Indemnifiable Claim to which the Indemnitee is or could have been a party unless such
settlement solely involves the payment of money and includes a complete and unconditional release of the Indemnitee from all liability
on any claims that are the subject matter of such Indemnifiable Claim. Neither the Company nor Indemnitee shall unreasonably withhold
its consent to any proposed settlement; provided that Indemnitee may withhold consent to any settlement that does not provide a complete
and unconditional release of Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Mutual Acknowledgment</U>. Both the Company and the Indemnitee acknowledge that in certain instances, Federal law or applicable public
policy may prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. Indemnitee understands
and acknowledges that the Company may be required in the future to undertake to the Securities and Exchange Commission to submit the
question of indemnification to a court in certain circumstances for a determination of the Company&rsquo;s right under public policy
to indemnify Indemnitee and, in that event, the Indemnitee&rsquo;s rights and the Company&rsquo;s obligations hereunder shall be subject
to that determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<U>Successors and Binding Agreement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement shall be binding upon and inure to the benefit of the Company and any successor to the Company, including, without limitation,
any Person acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger,
consolidation, reorganization, or otherwise (and such successor will thereafter be deemed the &ldquo;Company&rdquo; for purposes of this
Agreement), but shall not otherwise be assignable or delegable by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
This Agreement shall inure to the benefit of and be enforceable by the Indemnitee&rsquo;s personal or legal representatives, executors,
administrators, heirs, distributees, legatees, and other successors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
This Agreement is personal in nature and neither of the parties hereto shall, without the consent of the other, assign or delegate this
Agreement or any rights or obligations hereunder except as expressly provided in Sections 17(a) and 17(b). Without limiting the generality
or effect of the foregoing, Indemnitee&rsquo;s right to receive payments hereunder shall not be assignable, whether by pledge, creation
of a security interest, or otherwise, other than by a transfer by the Indemnitee&rsquo;s will or by the laws of descent and distribution,
and, in the event of any attempted assignment or transfer contrary to this Section 17(c), the Company shall have no liability to pay
any amount so attempted to be assigned or transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<U>Notices</U>. For all purposes of this Agreement, all communications, including without limitation notices, consents, requests, or
approvals, required or permitted to be given hereunder must be in writing and shall be deemed to have been duly given when hand delivered,
email with read receipt (legal@lifemd.com), or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed),
or one business day after having been sent for next-day delivery by a nationally recognized overnight courier service, addressed to the
Company (to the attention of the General Counsel of the Company) and to Indemnitee at the applicable address shown on the signature page
hereto, or to such other address as any party hereto may have furnished to the other in writing and in accordance herewith, except that
notices of changes of address will be effective only upon receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Governing Law</U>. The validity, interpretation, construction, and performance of this Agreement shall be governed by and construed
in accordance with the substantive laws of the State of Delaware, without giving effect to the principles of conflict of laws of such
State. The Company and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the State of Delaware for all
purposes in connection with any action or proceeding which arises out of or relates to this Agreement, waive all procedural objections
to suit in that jurisdiction, including, without limitation, objections as to venue or inconvenience, agree that service in any such
action may be made by notice given in accordance with Section 18 and also agree that any action instituted under this Agreement shall
be brought only in the Chancery Court of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Dispute Resolution</U>. In the event of any dispute arising under or pursuant to this Agreement, the parties agree to attempt to resolve
the dispute in a commercially reasonable fashion before instituting any litigation (with the exception of emergency injunctive relief).
If the parties are unable to resolve the dispute within thirty (30) days, then the parties agree to mediate the dispute with a mutually
agreed upon mediator in New York, NY. If the parties cannot agree upon a mediator within ten (10) days after either party shall first
request commencement of mediation, each party will select a mediator within five (5) days thereof, and those mediators shall select the
mediator to be used. The mediation shall be scheduled within thirty (30) days following the selection of the mediator. The parties further
agree that any applicable statute of limitations will be tolled for the period of time from the date mediation is requested until 14
days following the mediation. If the mediation does not resolve the dispute, then the parties irrevocably and unconditionally (i) agree
that any action or proceeding arising out of or in connection with this Agreement shall be brought in the Chancery Court of the State
of Delaware (the &ldquo;<U>Delaware Court</U>&rdquo;), and not in any other state or federal court in the United States of America or
any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action
or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action
or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding
brought in the Delaware Court has been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Validity</U>. If any provision of this Agreement or the application of any provision hereof to any Person or circumstance is held
invalid, unenforceable, or otherwise illegal, the remainder of this Agreement and the application of such provision to any other Person
or circumstance shall not be affected, and the provision so held to be invalid, unenforceable, or otherwise illegal shall be reformed
to the extent, and only to the extent, necessary to make it enforceable, valid, or legal. In the event that any court or other adjudicative
body shall decline to reform any provision of this Agreement held to be invalid, unenforceable, or otherwise illegal as contemplated
by the immediately preceding sentence, the parties hereto shall take all such action as may be necessary or appropriate to replace the
provision so held to be invalid, unenforceable, or otherwise illegal with one or more alternative provisions that effectuate the purpose
and intent of the original provisions of this Agreement as fully as possible without being invalid, unenforceable, or otherwise illegal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Miscellaneous</U>. No provision of this Agreement may be waived, modified, or discharged unless such waiver, modification or discharge
is agreed to in writing signed by Indemnitee and the Company. No waiver by either party hereto at any time of any breach by the other
party hereto or compliance with any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver
of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral
or otherwise, expressed or implied with respect to the subject matter hereof have been made by either party hereto that is not set forth
expressly in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
<U>Certain Interpretive Matters</U>. Unless the context of this Agreement otherwise requires, (1) &ldquo;it&rdquo; or &ldquo;its&rdquo;
or words of any gender include each other gender, (2) words using the singular or plural number also include the plural or singular number,
respectively, (3) the terms &ldquo;hereof,&rdquo; &ldquo;herein,&rdquo; &ldquo;hereby&rdquo; and derivative or similar words refer to
this entire Agreement, (4) the terms &ldquo;Article,&rdquo; &ldquo;Section,&rdquo; &ldquo;Annex&rdquo; or &ldquo;Exhibit&rdquo; refer
to the specified Article, Section, Annex, or Exhibit of or to this Agreement, (5) the terms &ldquo;include,&rdquo; &ldquo;includes&rdquo;
and &ldquo;including&rdquo; will be deemed to be followed by the words &ldquo;without limitation&rdquo; (whether or not so expressed),
and (6) the word &ldquo;or&rdquo; is disjunctive but not exclusive. Whenever this Agreement refers to a number of days, such number will
refer to calendar days unless business days are specified and whenever action must be taken (including the giving of notice or the delivery
of documents) under this Agreement during a certain period of time or by a particular date that ends or occurs on a non-business day,
then such period or date will be extended until the immediately following business day. As used herein, <B><I>&ldquo;business day&rdquo;
</I></B>means any day other than Saturday, Sunday, or a United States federal holiday.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
<U>Entire Agreement</U>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both
written and oral, between the parties hereto with respect to the subject matter of this Agreement. Any prior agreements or understandings
between the parties hereto with respect to indemnification are hereby terminated and of no further force or effect. This Agreement is
not the exclusive means of securing indemnification rights of Indemnitee and is in addition to any rights Indemnitee may have under any
Constituent Documents or Delaware Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
<U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all
of which together shall constitute one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.
<U>Duration of Agreement</U>. This Agreement shall continue until and terminate upon the later of: (a) six years after the date that
the Indemnitee shall have ceased to serve as a director, officer, employee, agent, or fiduciary of the Company or of any other corporation,
partnership, joint venture, trust, employee benefit plan, or other enterprise which the Indemnitee served at the request of the Company;
(b) the expiration of the applicable statutes of limitations pertaining to any and all potential proceedings covered by the indemnification
provided for herein; or (c) the final termination of all pending proceedings in respect of which the Indemnitee is granted rights of
indemnification or advancement of Expenses hereunder and of any proceeding commenced by the Indemnitee pursuant to this Agreement relating
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[-Signature
Page Follows-]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Indemnitee has executed, and the Company has caused its duly authorized representative to execute this Agreement as
of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">LIFEMD, INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><I>/s/ Justin Schreiber</I></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Justin Schreiber</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold"><B>INDEMNITEE</B>:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ Dr. Joan LaRovere</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Dr. Joan LaRovere, an individual</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page To Director And Officer Indemnification Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIFEMD,
INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
STOCK AWARD AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
RESTRICTED STOCK AWARD (this &ldquo;<B>Agreement</B>&rdquo;) is granted as of February 9, 2023 (the &ldquo;<B>Grant Date</B>&rdquo;),
and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the &ldquo;<B>Agreement</B>&rdquo;) between LifeMD, Inc. (the &ldquo;<B>Company</B>&rdquo;),
and Dr. Joan LaRovere (the &ldquo;<B>Director</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to grant the Director, shares of the Company&rsquo;s Common Stock, $0.01 par value (&ldquo;<B>Shares</B>&rdquo;),
subject to certain restrictions as set forth in this Agreement (this &ldquo;<B>Restricted Stock Award</B>&rdquo;), pursuant to the LifeMD,
Inc. 2020 Equity Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;) and any Amendments thereto (capitalized terms not otherwise defined herein
shall have the same meanings as in the Plan);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS<B>,
</B>the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) has determined that it would be to the advantage and best interest of the
Company and its stockholders to grant the Shares herein to the Director; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Grant of Restricted Shares</U>. Subject to the terms and conditions of the Plan and the additional terms and conditions set forth
in this Agreement, the Company hereby grants to the Director a restricted Shares award of Seventy Five Thousand (75,000) Shares (the
&ldquo;<B>Restricted Shares</B>&rdquo;). The Restricted Shares shall vest in accordance with Section 2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Vesting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Thirty-Seven Thousand Five Hundred (37,500) Restricted Shares shall vest upon the execution of the Director Agreement dated February
9, 2023 between the Company and the Director, and Thirty-Seven Thousand Five Hundred (37,500) Restricted Shares shall vest on the two-year
anniversary of the Grant Date, subject to the terms herein and the Director continuing in service on the Board through each applicable
vesting date. Notwithstanding the foregoing, the Restricted Shares shall vest upon the termination of the services provided to the Company
by the Director in her capacity as a director of the Company on account of being removed from such role or otherwise not being asked
to stand for re-election for reasons other than Cause (as that term is defined in a service and/or director agreement of such Director,
or if such term or terms is not defined in a service and/or director agreement or there is not a service agreement, as defined by the
Plan). If terminated for Cause, the Restricted Shares shall vest in a pro rata fashion up until the point of time that served as the
basis for termination for Cause. Similarly, in the case of death or disability, the Restricted Shares shall vest in a pro rata fashion
up until the point in time of death or disability. In lieu of fractional vesting, the number of Restricted Shares shall be rounded up
each time until fractional Restricted Shares are eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
However, notwithstanding any other provisions of this Agreement, at the option of the Board in its sole and absolute discretion, all
Restricted Shares shall be immediately forfeited in the even any of the following events occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Director purchases or sells securities of the Company without written authorization in accordance with the Company&rsquo;s insider
trading policy then in effect, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Director (A) discloses, publishes or authorizes anyone else to use, disclose or publish, without the prior written consent of the
Company, any proprietary or confidential information of the Company, including, without limitation, any information relating to existing
or potential customers, business methods, financial information, trade or industry practices, sales and marketing strategies, employee
information, vendor lists, business strategies, intellectual property, trade secrets or any other proprietary or confidential information
or (B) directly or indirectly uses any such proprietary or confidential information for the individual benefit of the Director or the
benefit of a third party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
During the term of the Director&rsquo;s service and for a period of one (1) year thereafter, the Director disrupts or damages, impairs,
or interferes with the business of the Company or its Affiliates by recruiting, soliciting or otherwise inducing any of their respective
directors or employees to enter into employment or other relationship with any other business entity, or terminate or materially diminish
their relationship with the Company or its Affiliates, as applicable. Notably, Director has pre-existing relationships, as well as those
created through the ordinary course of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical
School, iSelect Fund, Virtue Foundation, and others&mdash;none of which will be deemed a violation of this provision or this Agreement
now or into the future, so long as there is no malicious intent to violate this Agreement through such pre-existing relationships;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
During the term of the Director&rsquo;s service and for a period of one (1) year thereafter, the Director solicits or directs business
of any person or entity who is (A) a customer of the Company or its Affiliates at any time or (B) solicited to be a &ldquo;prospective
customer&rdquo; of the Company or its Affiliates, in any case either for such Director or for any other person or entity. For purposes
of this clause (v), &ldquo;prospective customer&rdquo; means a person or entity who contacted, or is contacted by, the Company or its
Affiliates regarding the provision of services to or on behalf of such person or entity; provided that the Director has actual knowledge
of such prospective customer. Notably, Director has pre-existing relationships, as well as those created through the ordinary course
of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation,
and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the future, so long as there
is no malicious intent to violate this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Director fails to reasonably cooperate to effect a smooth transition of the Director&rsquo;s duties and to ensure that the Company
is apprised of the status of all matters the Director is managing or is unavailable for consultation after termination of the Director&rsquo;s
service if such availability is a condition of any agreement to which the Company and the Director are parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
The Director fails to assign all of such Director&rsquo;s rights, title and interest in and to any and all ideas, inventions, formulas,
source codes, techniques, processes, concepts, systems, programs, software, computer data bases, trademarks, service marks, brand names,
trade names, compilations, documents, data, notes, designs, drawings, technical data and/or training materials, including improvements
thereto or derivatives therefrom, whether or not patentable or subject to copyright or trademark or trade secret protection, developed
and produced by the Director used or intended for use by or on behalf of the Company or the Company&rsquo;s clients; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
The Director acts in a disloyal manner to the Company, such as making comments, whether oral or in writing, that tend to disparage or
injure (i) the reputation or business of the Company or its Affiliates, or is likely to result in discredit to, or loss of business,
reputation or goodwill of, the Company or its Affiliates or (ii) its directors, officers or stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the Restricted Shares shall, to the extent it is then unvested, vest immediately prior to the closing for any Change
of Control. As used herein, &ldquo;<B>Change of Control</B>&rdquo; means (i) a <I>bona fide </I>transfer or series of related transfers
of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect
a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used
herein, &ldquo;<B>Group</B>&rdquo; means any group or syndicate that would be considered a &ldquo;person&rdquo; for purposes of Section
13(d) of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
For purposes of this Agreement, &ldquo;<B>Affiliate</B>&rdquo; means with respect to a person or entity, any other person or entity controlled
by, in control of or under common control with such person or entity, and &ldquo;controlled,&rdquo; &ldquo;controlled by,&rdquo; and
&ldquo;under common control with&rdquo; shall mean direct or indirect possession of the power to direct or cause the direction of management
policies (whether through ownership of voting securities, by contract or otherwise, of a person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Representations and Warranties; Acknowledgements</U>. In connection with the grant of the Restricted Shares hereunder, the Director
represents and warrants to the Company that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Director is acquiring Restricted Shares for Director&rsquo;s own account, not as a nominee or agent, for investment only and not
with a view towards, or for resale in connection with, the public sale or distribution thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Director understands that: (a) the Restricted Shares have not been registered under the Securities Act of 1933 as amended (the &ldquo;<B>Securities
Act</B>&rdquo;), or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered thereunder or (B) sold in reliance on an exemption therefrom; and (b) neither the Company nor any other person is under any
obligation to register such securities under the Securities Act or any state securities laws or to comply with the terms and conditions
of any exemption thereunder. In this regard, the Director represents that the Director is familiar with SEC Rule 144, and understands
the resale limitations imposed thereby and by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Director is able to bear the economic risk of the Director&rsquo;s investment in the Shares for an indefinite period of time because
the Restricted Shares have not been registered under the Securities Act and, therefore, cannot be sold unless subsequently registered
under the Securities Act or an exemption from such registration is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Director and the Director&rsquo;s advisers have had an opportunity to ask questions and receive answers concerning the terms and
conditions of the offering of the Shares as the Director and the Director&rsquo;s advisers have requested and have had full and free
access and opportunity to inspect, review, examine, and inquire about such other information concerning the Company and its Affiliates
as they have requested. The Director and the Director&rsquo;s advisers have also been provided with an opportunity to review and ask
questions about the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Director has had an opportunity to consult with independent legal counsel regarding the Director&rsquo;s rights and obligations under
this Agreement and the Plan, and fully understands the terms and conditions contained herein. The Director is not relying on the Company
or any of its employees, agents, or representatives with respect to the legal, tax, economic, and related considerations of an investment
in the Shares. The Director understands that in the future the Shares may significantly increase or decrease in value, and the Company
has not made any representation to the Director about the potential future value of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Director understands and agrees that the investment in the Company involves a high degree of risk and that no guarantees have been
made or can be made with respect to the future value of the Restricted Shares or the future profitability or success of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Termination of Relationship</U>. Upon the termination of the Director&rsquo;s service on the Board, all unvested Shares of Restricted
Shares shall be automatically and irrefutably forfeited. If such forfeiture occurs, the Director shall execute and deliver to the Company
any and all further documents (including an Assignment Separate From Certificate) as the Company reasonably requests to further document
the forfeiture. As used in this Agreement, &ldquo;<B>service</B>&rdquo;, &ldquo;<B>termination of service</B>&rdquo; and like terms shall
be construed to include any employment or consulting relationship with the Company or its Affiliates. For purposes of this Agreement,
a change from performing service on the Board to such an employment or consulting relationship or vice versa shall not be treated as
a termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Redemption</U>. If any of the events specified in Section 2(b) of this Agreement occur within one (1) year from the last date of the
Director&rsquo;s service (the &ldquo;<B>Termination Date</B>&rdquo;), all Restricted Shares that vested during the one (1) year period
ending on the Termination Date shall be forfeited and forthwith surrendered by the Director to the Company within ten (10) days after
the Director receives written demand from the Company for such Restricted Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Certificates</U>. Certificates evidencing the Restricted Shares shall be issued by the Company and shall be registered in the Director&rsquo;s
name promptly after the date the shares are vested. No certificates shall be issued for fractional shares, but rather rounded up to the
next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Rights as a Stockholder</U>. Neither the Director, the Director&rsquo;s estate, nor the Transferee have any rights as a shareholder
with respect to any Common Stock covered by the Restricted Shares unless and until such Restricted Shares have vested. &ldquo;<B>Transferee</B>&rdquo;
shall mean an individual to whom such Director&rsquo;s vested Restricted Shares are transferred by will or by the laws of descent and
distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Legend on Certificates</U>. The certificates representing the vested Restricted Shares delivered to the Director as contemplated by
Section 5 shall bear such legends, and be subject to such stop transfer orders, as the Company may deem advisable to give notice of restrictions
imposed by this Agreement, the Plan, the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock
exchange upon which such Shares are listed, or any applicable law. The Company may cause a legend or legends to be put on any such certificates
to make appropriate reference to such restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Transferability.</U> To the extent that the Restricted Shares are then unvested, the Director shall not transfer, sell, assign, pledge,
hypothecate or otherwise dispose of the Restricted Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Retention by the Company.</U> Nothing contained in this Agreement or in any other agreement entered into by the Company and the Director
contemporaneously with the execution of this Agreement (i) shall be deemed to obligate the Company or any of its Affiliates to employ
or retain the Director in any capacity whatsoever, or (ii) shall prohibit or restrict the Company or any of its Affiliates from terminating
the service, if any, of the Director at any time or for any reason whatsoever, and the Director hereby acknowledges and agrees that neither
the Company nor any other Person has made any representations or promises whatsoever to the Director concerning the Director&rsquo;s
service or continued service by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Sale of Shares Acquired</U>. If the Director is an officer (as defined by Section 16(b) of the Securities Exchange Act of 1934, as
amended (&ldquo;<B>Section 16(b)</B>&rdquo;), any shares of the Company&rsquo;s Common Stock acquired pursuant to Restricted Stock Awards
granted hereunder cannot be sold by the Director, subject to registration or an exemption from registration such as to Rule 144 promulgated
under the Securities Act, until at least six (6) months elapse from the date of grant of this Restricted Stock Award, except in the case
of death or disability or if the grant was exempt from the short-swing profit provisions of Section 16(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Withholding</U>. The Director acknowledges that the Director is responsible for all liability for applicable tax related to the issuance
or vesting of this Restricted Stock Award. Unless the Director uses a designated broker to sell Shares with an aggregate fair market
value sufficient to cover the amount required to be withheld by the Company, or the Director delivers in cash or certified check the
amount required to be withheld by the Company, the Company will issue the number of Shares owed to the Director under this Restricted
Stock Award less a number of Shares equal to, in the aggregate, the amount of applicable tax related to the delivery of such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Adjustments</U>. The Restricted Shares under this Agreement shall be subject to the terms of the Plan, including but not limited to
Section 3(b) (Changes in Stock) and 3(c) (Sale Events) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Limitation on Obligations</U>. The Company&rsquo;s obligation with respect to the Restricted Shares granted hereunder is limited solely
to the delivery to the Director of Shares on the date when such Shares are due to be delivered hereunder, and in no way shall the Company
become obligated to pay cash in respect of such obligation. This Restricted Stock Award shall not be secured by any specific assets of
the Company, nor shall any assets of the Company be designated as attributable or allocated to the satisfaction of the Company&rsquo;s
obligations under this Agreement. In addition, the Company shall not be liable to the Director for damages relating to any delays in
issuing the share certificates to him/her (or her designated entities), any loss of the certificates, or any mistakes or errors in the
issuance of the certificates or in the certificates themselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Securities Laws</U>. Upon the vesting of any Restricted Shares, the Company may require the Director to make or enter into such written
representations, warranties and agreements as the Committee may reasonably request solely to comply with applicable securities laws or
with this Agreement. The granting of the Restricted Shares hereunder shall be subject to all applicable laws, rules, and regulations
and to such approvals of any governmental agencies as may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<U>Arbitration</U>. Any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application,
implementation, breach or enforcement which the parties hereto are unable to resolve by mutual agreement, shall be settled by submission
by either party of the controversy, claim or dispute to binding arbitration in New York County, New York (unless the parties agree in
writing to a different location), before a single arbitrator in accordance with the rules of the American Arbitration Association then
in effect. The decision and award made by the arbitrator shall be final, binding, and conclusive on all parties hereto for all purposes,
and judgment may be entered thereon in any court having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<U>Governing Law.</U> This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether
relating to its execution, its validity, the obligations provided herein or performance, shall be governed or interpreted according to
the laws of the State of Delaware without regard to choice of law considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Restricted Shares Award Subject to Plan</U>. This Restricted Stock Award shall be subject to the terms and provisions of the Plan.
In the event of any conflict between this Agreement and the Plan, the terms of this Agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Signature in Counterparts</U>. This Agreement may be signed in multiple counterparts, each of which shall be deemed an original and
all of which taken together shall be deemed one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Copy of Plan</U>. By execution of this Agreement, the Director acknowledges receipt of a copy of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
<U>New Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any shares of capital stock of the Company or any successor thereto (&ldquo;<B>New Shares</B>&rdquo;) issued by the Company from time
to time (including without limitation in any stock split or stock dividend) with respect to Restricted Shares (&ldquo;<B>Old Shares</B>&rdquo;)
shall also be treated as Restricted Shares for all purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The New Shares so issued shall at all times be vested in the same proportion as the Old Shares are vested. For example: (i) if none of
the Old Shares are vested as of the date that the New Shares are issued, then none of the New Shares will be vested when issued, (ii)
if, from time to time, 25% of the Old Shares become vested at any later date, then 25% of the New Shares shall also become vested on
that date; and (ii) if all of the Old Shares are vested on a date, then all of the New Shares shall be vested on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The New Shares shall be subject to this Agreement, including without limitation Section 3 thereof, to the same extent as the Old Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have executed this Restricted Stock Award Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Courier New, Courier, Monospace; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: <U></U></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Justin Schreiber</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin Schreiber</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: &nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Courier New, Courier, Monospace; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Joan LaRovere</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Joan LaRovere</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
NON-QUALIFIED STOCK OPTION is granted as of February 9, 2023 (the &ldquo;<B>Grant Date</B>&rdquo;), and reflected in this NON-QUALIFIED
STOCK OPTION AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;) by and between LifeMD, Inc. (the &ldquo;<B>Company</B>&rdquo;) and Dr. Joan
LaRovere (the &ldquo;<B>Optionee</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
pursuant to the authority of the Board of Directors (the &ldquo;<B>Board</B>&rdquo;), the Company has granted the Optionee the right
to purchase common stock, $0.01 par value per share (&ldquo;<B>Common Stock</B>&rdquo;) of the Company pursuant to stock options, at
not less than 100% of fair market value, granted under the LifeMD, Inc. 2020 Equity and Incentive Plan and any Amendments thereto, approved
by the Board (the &ldquo;Plan&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW
THEREFORE, in consideration of the mutual covenants and promises hereafter set forth and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Grant of Non-Qualified Options</U>. The Company hereby irrevocably grants to the Optionee, as a matter of separate agreement and not
in lieu of salary or other compensation for services, the right and option to purchase all or any part of an aggregate of Thirty Seven
Thousand Five Hundred (37,500) shares of authorized but unissued or treasury common stock of the Company (the &ldquo;<B>Options</B>&rdquo;)
on the terms and conditions herein set forth. The Options are not intended to be Incentive Stock Options as defined by Section 422 of
the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Price</U>. The exercise price of the shares of Common Stock subject to the Options granted hereunder shall be $1.89.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Vesting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Options shall vest on the two-year anniversary of the Grant Date, subject to the terms herein and the Optionee continuing to perform
services for the Company on each applicable vesting date. Notwithstanding the foregoing, the Options shall vest upon the termination
of the services provided to the Company by Optionee in her capacity as a director of the Company on account of being removed from such
role or otherwise not being asked to stand for re-election for reasons other than Cause (as that term is defined in a service and/or
director agreement of such Optionee, or if such term or terms is not defined in a service and/or director agreement or there is not a
service agreement, as defined by the Plan). If terminated for Cause, the Options shall vest in a pro rata fashion up until the point
of time that served as the basis for termination for Cause. Similarly, in the case of death or disability, the Options shall vest in
a pro rata fashion up until the point in time of death or disability. In lieu of fractional vesting, the number of Options shall be rounded
up each time until fractional Options are eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Subject to Sections 3(c) and 4 of this Agreement, Options may be exercised by providing to the Company the Notice of Option Exercise
in the form attached hereto as <U>Exhibit A</U> after vesting and remain exercisable until 5:30 p.m. New York time on the date that is
the fifth (5th) year anniversary of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
However, notwithstanding any other provision of this Agreement, at the option of the Board in its sole and absolute discretion, all Options
shall be immediately forfeited in the event any of the following events occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Optionee purchases or sells securities of the Company without written authorization in accordance with the Company&rsquo;s insider
trading policy then in effect, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Optionee (A) discloses, publishes or authorizes anyone else to use, disclose or publish, without the prior written consent of the
Company, any proprietary or confidential information of the Company, including, without limitation, any information relating to existing
or potential customers, business methods, financial information, trade or industry practices, sales and marketing strategies, employee
information, vendor lists, business strategies, intellectual property, trade secrets or any other proprietary or confidential information
or (B) directly or indirectly uses any such proprietary or confidential information for the individual benefit of the Optionee or the
benefit of a third party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
During the term of service and for a period of one (1) year thereafter, the Optionee disrupts or damages, impairs or interferes with
the business of the Company or its Affiliates by recruiting, soliciting or otherwise inducing any of their respective employees to enter
into employment or other relationship with any other business entity, or terminate or materially diminish their relationship with the
Company or its Affiliates, as applicable. Notably, Director has pre-existing relationships, as well as those created through the ordinary
course of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue
Foundation, and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the future, so
long as there is no malicious intent to violate this Agreement through such pre-existing relationships;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
During the term of employment and for a period of one (1) year thereafter, the Optionee solicits or directs business of any person or
entity who is (A) a customer of the Company or its Affiliates at any time or (B) solicited to be a &ldquo;prospective customer&rdquo;
of the Company or its Affiliates, in any case either for such Optionee or for any other person or entity. For purposes of this clause
(v), &ldquo;<B>prospective customer</B>&rdquo; means a person or entity who contacted, or is contacted by, the Company or its Affiliates
regarding the provision of services to or on behalf of such person or entity; <I>provided </I>that the Optionee has actual knowledge
of such prospective customer. Notably, Director has pre-existing relationships, as well as those created through the ordinary course
of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation,
and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the future, so long as there
is no malicious intent to violate this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Optionee fails to reasonably cooperate to effect a smooth transition of the Optionee&rsquo;s duties and to ensure that the Company
is apprised of the status of all matters the Optionee is handling or is unavailable for consultation after termination of employment
of the Optionee if such availability is a condition of any agreement to which the Company and the Optionee are parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Optionee fails to assign all of such Optionee&rsquo;s rights, title and interest in and to any and all ideas, inventions, formulas,
source codes, techniques, processes, concepts, systems, programs, software, computer data bases, trademarks, service marks, brand names,
trade names, compilations, documents, data, notes, designs, drawings, technical data and/or training materials, including improvements
thereto or derivatives therefrom, whether or not patentable or subject to copyright or trademark or trade secret protection, developed
and produced by the Optionee used or intended for use by or on behalf of the Company or the Company&rsquo;s clients; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Optionee acts in a disloyal manner to the Company, such as making comments, whether oral or in writing, that tend to disparage or
injure (i) the reputation or business of the Company or its Affiliates, or is likely to result in discredit to, or loss of business,
reputation or goodwill of, the Company or its Affiliates or (ii) its directors, officers or stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the Options shall, to the extent then unvested, vest immediately prior to the closing for any Change of Control. As
used herein, &ldquo;<B>Change of Control</B>&rdquo; means (i) a bona fide transfer or series of related transfers of shares of Common
Stock to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect a
majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used herein,
&ldquo;<B>Group</B>&rdquo; means any group or syndicate that would be considered a &ldquo;person&rdquo; for purposes of Section 13(d)
of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For purposes of this Agreement, &ldquo;<B>Affiliate</B>&rdquo; means with respect to a person or entity, any other person or entity controlled
by, in control of or under common control with such person or entity, and &ldquo;controlled,&rdquo; &ldquo;controlled by,&rdquo; and
&ldquo;under common control with&rdquo; shall mean direct or indirect possession of the power to direct or cause the direction of management
or policies (whether through ownership of voting securities, by contract or otherwise) of a person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Representations and Warranties; Acknowledgements</U>. In connection with the grant of the Award Shares hereunder, Optionee represents
and warrants to the Company that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Optionee is able to bear the economic risk of Optionee&rsquo;s investment in the Shares for an indefinite period of time because the
Award Shares have not been registered under the Securities Act and, therefore, cannot be sold unless subsequently registered under the
Securities Act or an exemption from such registration is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Optionee and Optionee&rsquo;s advisers have had an opportunity to ask questions and receive answers concerning the terms and conditions
of the offering of the Shares as Optionee and Optionee&rsquo;s advisers have requested and have had full and free access and opportunity
to inspect, review, examine, and inquire about such other information concerning the Company and its Affiliates as they have requested.
Optionee and Optionee&rsquo;s advisers have also been provided an opportunity to review and ask questions about the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Optionee has had an opportunity to consult with independent legal counsel regarding Optionee&rsquo;s rights and obligations under this
Agreement and the Plan, and fully understands the terms and conditions contained herein. Optionee is not relying on the Company or any
of its Optionees, agents, or representatives with respect to the legal, tax, economic, and related considerations of an investment in
the Shares. Optionee understands that in the future the Shares may significantly increase or decrease in value, and the Company has not
made any representation to the Optionee about the potential future value of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Optionee understands and agrees that the investment in the Company involves a high degree of risk and that no guarantees have been made
or can be made with respect to the future value of the Award Shares or the future profitability or success of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Termination of Relationship</U>. Upon the Optionee&rsquo;s termination of service, all unvested Options shall be automatically and
irrefutably forfeited. For purposes of this Agreement, terms like &ldquo;service&rdquo; and &ldquo;termination of service&rdquo; refer
to service with the Company and all Affiliates of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If for any reason, except death or disability as provided below, the Optionee ceases to perform the services for which the Options were
granted, the Optionee shall have the right within three (3) months from the date of cessation to exercise the Optionee&rsquo;s vested
Options, subject to Section 3(c) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If the Optionee shall die while performing services for the Company, such Optionee&rsquo;s estate or any Transferee (as defined hereinafter)
shall have the right within twelve (12) months from the date of death to exercise the Optionee&rsquo;s vested Options, subject to Section
3(c) hereof. For the purpose of this Agreement, &ldquo;<B>Transferee</B>&rdquo; shall mean an individual to whom such Optionee&rsquo;s
vested Options are transferred by will or by the laws of descent and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If the Optionee shall become disabled while performing services for the Company within the meaning of Section 22(e)(3) of the Code, the
three-month period referred to in Section 4(a) of this Agreement shall be extended to one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For purposes of this Agreement, a change from performing service on the Board to an employment or consulting relationship or vice versa
shall not be treated as a termination of service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Profits on the Sale of Certain Shares; Redemption</U>. If any of the events specified in Section 3(c) of this Agreement occur within
one (1) year from the last date the Optionee performed services for which the Options were granted (the &ldquo;<B>Termination Date</B>&rdquo;),
all profits earned from the sale of the Company&rsquo;s securities, including the sale of shares of Common Stock underlying the Options,
during the two (2) year period commencing one (1) year prior to the Termination Date shall be forfeited and forthwith paid by the Optionee
to the Company within ten (10) days after the Optionee receives written demand from the Company for such payment and a copy of the documentation
of the sale, including, without limitation, the purchase price therefor. Further, in such event, the Company may at its option redeem
shares of Common Stock acquired upon exercise of the Options by payment of the exercise price to the Optionee. The Company&rsquo;s rights
under this Section 5 do not lapse one year from the Termination Date, but are a contract right subject to any appropriate statutory limitation
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Transfer</U>. No transfer of the Options by the Optionee by will or by the laws of descent and distribution shall be effective to
bind the Company unless the Company shall have been furnished with written notice thereof and a copy of the letters testamentary or such
other evidence as the Board may deem necessary to establish the authority of the estate and the acceptance by the Transferee or Transferees
of the terms and conditions of the Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Method of Exercise</U>. The Options shall be exercisable by a written notice in the manner and form identified on Exhibit A hereto
which information shall include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
state the election to exercise the Options, the number of shares to be exercised, the natural person in whose name the stock certificate
or certificates for such shares of Common Stock is to be registered and such person&rsquo;s address and social security number (or if
more than one, the names, addresses and social security numbers of such persons);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
contain such representations and agreements as to the holder&rsquo;s investment intent with respect to such shares of Common Stock as
set forth in Section 11 hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
be signed by the person or persons entitled to exercise the Options and, if the Options are being exercised by any person or persons
other than the Optionee, be accompanied by proof, satisfactory to counsel for the Company, of the right of such person or persons to
exercise the Options; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
be accompanied by full payment of the purchase or exercise price and all applicable required tax withholding in United States dollars
in cash or by bank or cashier&rsquo;s check, certified check or money order or (i) by executing a &ldquo;sell-to-cover cashless exercise&rdquo;
through the Company&rsquo;s designated broker to promptly deliver to the Company the amount of proceeds from the sale of shares having
a fair market value equal to the purchase price and all applicable required tax withholding on the date of exercise; (ii) by executing
a &ldquo;net cashless exercise&rdquo; by having the Company withhold Option shares equivalent in value to the exercise price and all
applicable required tax withholding; or (iii) by tendering shares of Common Stock equivalent in value to the exercise price and all applicable
required tax withholding, subject to applicable securities laws and share holding period requirements necessary to avoid a charge to
the Company&rsquo;s earnings for financial accounting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate or certificates for shares of Common Stock as to which the Options shall be exercised shall be registered in the name of
the person or persons exercising the Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Sale of Shares Acquired Upon Exercise of Options</U>. If the Optionee is an officer (as defined by Section 16(b) of the Securities
Exchange Act of 1934, as amended (&ldquo;<B>Section 16(b)</B>&rdquo;), any shares of the Company&rsquo;s Common Stock acquired pursuant
to Options granted hereunder cannot be sold by the Optionee, subject to registration or an exemption from registration such as to Rule
144 promulgated under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), until at least six (6) months
elapse from the date of grant of the Options, except in the case of death or disability or if the grant was exempt from the short-swing
profit provisions of Section 16(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Adjustments</U>. The Options under this Agreement shall be subject to the terms of the Plan, including but not limited to, Sections
3(b) (Changes in Stock) and 3(c) (Sale Events) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Necessity to Become Holder of Record</U>. Neither the Optionee, the Optionee&rsquo;s estate, nor the Transferee have any rights as
a shareholder with respect to any shares of Common Stock covered by the Options until such Optionee, estate or Transferee, as applicable,
shall have become the holder of record of such shares of Common Stock. No adjustment shall be made for cash dividends or cash distributions,
ordinary or extraordinary, in respect of such shares of Common Stock for which the record date is prior to the date on which such Optionee,
estate or Transferee, as applicable, shall become the holder of record thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Conditions to Exercise of Options</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In order to enable the Company to comply with the Securities Act and relevant state law, the Company may require the Optionee, the Optionee&rsquo;s
estate or any Transferee, as a condition of the exercise of the Options granted hereunder, to give written assurance satisfactory to
the Company that the shares of Common Stock subject to the Options are being acquired for such Optionee&rsquo;s, estate&rsquo;s or Transferee&rsquo;s,
as applicable, own account, for investment only, with no view to the distribution of same, and that any subsequent resale of any such
shares of Common Stock either shall be made pursuant to a registration statement under the Securities Act and applicable state law which
has become effective and is current with regard to the shares of Common Stock being sold, or shall be pursuant to an exemption from registration
under the Securities Act and applicable state law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Options are subject to the requirement that, if at any time the Board shall determine, in its sole and absolute discretion, that
the listing, registration or qualification of the shares of Common Stock subject to the Options upon any securities exchange or under
any state or federal law, or the consent or approval of any governmental regulatory body, is necessary as a condition of, or in connection
with the issue or purchase of such shares of Common Stock under the Options, the Options may not be exercised in whole or in part unless
such listing, registration, qualification, consent or approval shall have been effected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Severability</U>. In the event any parts of this Agreement are found to be void, the remaining provisions of this Agreement shall
nevertheless be binding with the same effect as though the void parts were deleted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Arbitration</U>. Any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application,
implementation, breach or enforcement which the parties hereto are unable to resolve by mutual agreement, shall be settled by submission
by either party of the controversy, claim or dispute to binding arbitration in New York County, New York (unless the parties agree in
writing to a different location), before a single arbitrator in accordance with the rules of the American Arbitration Association then
in effect. The decision and award made by the arbitrator shall be final, binding, and conclusive on all parties hereto for all purposes,
and judgment may be entered thereon in any court having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Benefit</U>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their legal representatives,
successors, and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Notices and Addresses</U>. All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing,
and shall be sufficiently given if delivered to the addressees in person, by FedEx or similar receipted delivery, or by facsimile delivery
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Optionee:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joan LaRovere </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>[***]</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236
    Fifth Avenue, Suite 400</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10001 </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>legal@lifemd.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
to such other address as either of them, by notice to the other, may designate from time to time. The transmission confirmation receipt
from the sender&rsquo;s facsimile machine shall be evidence of successful facsimile delivery. Time shall be counted to, or from, as the
case may be, the delivery in person or by mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<U>Attorney&rsquo;s Fees</U>. In the event that there is any controversy or claim arising out of or relating to this Agreement, or to
the interpretation, breach, or enforcement thereof, and any action or proceeding is commenced to enforce the provisions of this Agreement,
the prevailing party shall be entitled from the non-prevailing party to its reasonable attorneys&rsquo; fee, costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<U>Governing Law</U>. This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether
relating to its execution, its validity, the obligations provided herein or performance, shall be governed or interpreted according to
the laws of the State of Delaware without regard to choice of law considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Oral Evidence</U>. This Agreement, along with the Plan, a director and/or employment agreement, and any amendment thereto, constitute
the entire agreement between the parties hereto and supersedes all prior oral and written agreements between the parties hereto with
respect to the subject matter hereof. Neither this Agreement nor any provision hereof may be changed, waived, discharged or terminated
except by a statement in writing signed by the party or parties against which enforcement or the change, waiver discharge or termination
is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. The execution of this Agreement may be made by facsimile signature, which
shall be deemed to be an original.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Section Headings</U>. Section headings herein have been inserted for reference only and shall not be deemed to limit or otherwise
affect, in any matter, or be deemed to interpret in whole or in part, any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the parties hereto have set their hand the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIFEMD,
    INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Justin Schreiber</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Schreiber</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPTIONEE:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Joan LaRovere</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joan LaRovere</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
page to Non-qualified Stock Option Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF NOTICE OF OPTION EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:
LifeMD, Inc. (the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase __________ shares of Common Stock of the Company (the &ldquo;Shares&rdquo;) pursuant to the
terms of the Option Agreement by and between the Company and the undersigned dated as of __________ ___, 20__, and tenders herewith payment
of the exercise price in full as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;
    ]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    lawful money of the United States in the form of cash or by a bank check or cashier&rsquo;s check made payable by the undersigned
    to the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    lawful money of the United States in the form of a wire transfer to the account specified by the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of shares of a &ldquo;broker-assisted cashless exercise&rdquo; as described in Section 7(d) of the Option Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of shares of a &ldquo;net cashless exercise&rdquo; as described in Section 7(d) of the Option Agreement; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    &nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of shares of Common Stock (a &ldquo;stock-for-stock exercise&rdquo;) as described in Section 7(d) of the Option Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue a certificate or certificates representing the Shares in the name of the undersigned or in such other name as is specified
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares shall be delivered via overnight courier (with tracking information to be provided to the undersigned) to the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    ________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    _________________________</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPTIONEE</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Exhibit
A to Non-qualified Stock Option Agreement]</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: Red; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Appoints Dr. Joan LaRovere to its Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NEW
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YORK, February 10, 2023 &mdash; </FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">LifeMD,
Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company</FONT>, today announced the appointment of Dr. Joan LaRovere to its
Board of Directors. With Dr. LaRovere&rsquo;s appointment, LifeMD&rsquo;s Board will comprise nine directors, seven of whom are independent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are pleased to welcome Dr. LaRovere to the LifeMD Board,&rdquo; said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.
&ldquo;Dr. LaRovere&rsquo;s leadership and clinical experience at two of the top hospitals in the world, combined with her deep background
in healthcare data, analytics, machine learning, and artificial intelligence will be invaluable to LifeMD as we grow our business and
pursue our mission to increase access to high quality and affordable virtual care.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
LaRovere is Director of Innovation and Outcomes and an Attending Physician in Cardiovascular Critical Care at Boston Children&rsquo;s
Hospital, as well as an Assistant Professor of Pediatrics at Harvard Medical School since 2011. Before then, she was Chief of Pediatric
Intensive Care and a member of the Children&rsquo;s Services Management Committee at the Royal Brompton Hospital in London, where she
was also a member of the faculty at Imperial College School of Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
LaRovere is also the Co-Founder and Vice-President of the Virtue Foundation, an NGO with Special Consultative Status to the United Nations
that seeks to provide both short-term impactful and long-term sustainable development solutions to communities across the globe. She
is also an advisor and Delta V board member of the Martin Trust Center for MIT Entrepreneurship and a Healthcare Operating Partner with
iSelect Fund, a venture firm investing at the intersection of nutrition and healthcare. Dr. LaRovere holds a Bachelor of Arts in Visual
and Environmental Studies from Harvard University, a Master of Science in Genetics from the University of St. Andrews in Scotland, a
Doctorate in Medicine from Columbia University, and an MBA from the MIT Sloan School of Management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;I
have always been deeply passionate about using technology to expand access to affordable healthcare. I believe that LifeMD has built
a technology platform and affiliated medical group that will be a driving force in the next chapter of technology-enabled care in the
United States and maybe beyond,&rdquo; said Dr. Joan LaRovere. &ldquo;I am excited to be part of the team and look forward to using my
experience in medicine, technology, and entrepreneurship to maximize the company&rsquo;s success.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD
is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized
treatment for men&rsquo;s and women&rsquo;s health, allergy &amp; asthma, and dermatological conditions. By leveraging its proprietary
technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch
healthcare that is affordable to anyone. To learn more, go to LifeMD.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; predict,&rdquo; &ldquo;continue,&rdquo; and &ldquo;potential,&rdquo;
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, &ldquo;Risk Factors&rdquo; identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
was made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>marc@lifemd.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *8# 2(  A$! Q$!_\0
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M!ACK6=X6TV\L-3U^6Z@,:7-WYD))'SK@\TEHFBGK*+0W5O\ DH'A[_KE<?\
MH-=16!J-A=3>,M%O8X2UM!',)9,C"EEP*WZ4MD5#=^IYZFC:4?B)J5EJUC#,
M+Y!<VK2C.3_$!_A[5T?_  A/AK_H#6O_ 'R:F\0^'H->MH_WK6]Y V^WN8_O
M1M_A[5C1ZKXPTD>3?:*FJ*O2XM) I8#N5/>KNY+1F7+&+?,M/0T_^$)\-?\
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D_2M=C*' 55*YY)-1.2:Y8['7AJ$U-UJOQ/\  DHHHK(] __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lfmd-20230209.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKJmbP9z5Z8aekhvWB8bcm6byIgKJQPVy4M3+bmoXkG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LFMD="http://lifemd.com/20230209" elementFormDefault="qualified" targetNamespace="http://lifemd.com/20230209">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lifemd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20230209_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20230209_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20230209_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="LFMD_CommonStockParValue0.01PerShareMember" name="CommonStockParValue0.01PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" name="SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lfmd-20230209_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lifemd.com/role/Cover" xlink:href="lfmd-20230209.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lifemd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230209.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="loc_LFMDCommonStockParValue0.01PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDCommonStockParValue0.01PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230209.xsd#LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:label="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lfmd-20230209_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lfmd-20230209.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="LFMD_CommonStockParValue0.01PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LFMD_CommonStockParValue0.01PerShareMember" xlink:to="LFMD_CommonStockParValue0.01PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LFMD_CommonStockParValue0.01PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.01 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lfmd-20230209.xsd#LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:label="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:to="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_lbl" xml:lang="en-US">Series A Cumulative Perpetual Preferred Stock, $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lfmd-20230209_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lifemd.com/role/Cover" xlink:href="lfmd-20230209.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lifemd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230209.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="loc_LFMDCommonStockParValue0.01PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDCommonStockParValue0.01PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230209.xsd#LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:label="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140425185123568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIFEMD,
INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000948320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0238453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">236
Fifth Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">351-5907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember', window );">Common Stock, par value $0.01 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFMD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember', window );">Series A Cumulative Perpetual Preferred Stock, $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Series
    A Cumulative Perpetual Preferred Stock, $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFMDP<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LFMD="http://lifemd.com/20230209"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lfmd-20230209.xsd" xlink:type="simple"/>
    <context id="From2023-02-09to2023-02-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue0.01PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="From2023-02-092023-02-09_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-02-09to2023-02-09">0000948320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-02-09to2023-02-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-02-09to2023-02-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-09to2023-02-09">2023-02-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-02-09to2023-02-09">LIFEMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-09to2023-02-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-02-09to2023-02-09">001-39785</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-09to2023-02-09">76-0238453</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-09to2023-02-09">236 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-02-09to2023-02-09">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-09to2023-02-09">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-09to2023-02-09">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-09to2023-02-09">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-09to2023-02-09">(866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-09to2023-02-09">351-5907</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-02-09to2023-02-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-02-09to2023-02-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-02-09to2023-02-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-02-09to2023-02-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember">Common     Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember">LFMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-02-092023-02-09_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">Series     A Cumulative Perpetual Preferred Stock, $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-092023-02-09_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">LFMDP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-092023-02-09_custom_CommonStockParValue0.01PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-09to2023-02-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( 'J)2E8'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ >HE*5C?KFI[N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ >HE*5IE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !ZB4I6VK4_BZX$  !@$P
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ >HE*5N#T.HFJ @  , P   T              ( !\0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !ZB4I6EXJ[',     3 @  "P
M        @ '&#P  7W)E;',O+G)E;'-02P$"% ,4    " !ZB4I6JL0B%C,!
M   B @  #P              @ &O$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ >HE*5B0>FZ*M    ^ $  !H              ( !#Q(  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ >HE*5F60>9(9 0
MSP,  !,              ( !]!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  /A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lifemd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex10-3.htm</File>
    <File>ex99-1.htm</File>
    <File>lfmd-20230209.xsd</File>
    <File>lfmd-20230209_def.xml</File>
    <File>lfmd-20230209_lab.xml</File>
    <File>lfmd-20230209_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "lfmd-20230209_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lfmd-20230209_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lfmd-20230209_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lfmd-20230209.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "LFMD",
   "nsuri": "http://lifemd.com/20230209",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-02-09to2023-02-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lifemd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-02-09to2023-02-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "LFMD_CommonStockParValue0.01PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.01 per share"
       }
      }
     },
     "localname": "CommonStockParValue0.01PerShareMember",
     "nsuri": "http://lifemd.com/20230209",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Cumulative Perpetual Preferred Stock, $0.0001 per share"
       }
      }
     },
     "localname": "SeriesCumulativePerpetualPreferredStock0.0001PerShareMember",
     "nsuri": "http://lifemd.com/20230209",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-23-004330-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-004330-xbrl.zip
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M8S#+P=AC3:/27\@L\IY+T3:<Z&TOGC?\FKX(-CA=]N[2WN/I"2: 6\#EDK=
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MN)1^QK8.PHT<*=69VRF7ZRN8'J]@Y^""=\EKG-<H10]*RCG'!K>^83G+8G#
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MN#"^11N2V'1S)^>9EJ%*FE@C2J=EF>(A1-Z)%=BBSJ4C?>K(D5254(JB2V8
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M->"ZNSO:IDW1^_N[Z/V51N_O[Z+WN[OT(X9R<$<O4R*#X?OSB&2[F(@AR\X
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M'%Y]GF#2N%[QKOH(1O#0,YIG3)Y!#51M;G91\>LVE -;]:A>87;:&U.7>>L
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MG9/?_U<[)Z_^P%X@9@8%WR<.Y2J[??QJ//K]^.35T=NWT>\_'[TY>OTB).'
M*!"Q!*>L>UBST2M(5 97&:KZ+>AIE>30HP?(8]?IL-DH42$!"0VEU<.G6![
MULQDVYF*R5'\7=AM!)MXY;?4+GNPFVFV*67GW*"? )_(092^/'YQ1)E[KY[M
M;\X/^;1<-S^)[J(,E*O(IKL'4O7INI,>UUF1C;>*79C[/_P/W>2WZ]M1-[6.
MK_ M:7H/4++_T6$-3U:_+U<ZE\,O?;;(S#PZ(BF!L7,A$?KV=LKE3L/SXS='
MSTY>O_GFQO?I^U[W.O=@()&NN^,_TT[KO3EFWU.:G65IF^27Z<07R%#;&3Y#
MO?YGU^@Y*0=TCG]]>Y?^=>KA1X!"?MC975=J=_WP7V9W76>LQ_4_])_=S<2D
MC/_OY^.GQR?CD65E_ ;'H0OP379>;*?QB(VG;W ,WUI_GUH-';;]J^?1ZQ<O
MCI\=O0'K]?G1+Z^.X1^')\>O7T6'/[TY.OKEZ-7)-[DJ7^Y8?"&E%L,H'\M&
M&U/J (4/RWGTPDRK-JG6T8]Q=/?.W7N,BD=!>/Q$\%OV28%NL>7R],E>S 5Q
M4Q--UU1TTT+.?-JB&!%,BJ7V*J$/O,FR:'??@VT'-LS PS+@QICN\[O(S5<]
M<R!7CD\.7[Y]N),9UV$?'4HY6'LF?S(%I:\\\\[FR^1<09!>&=4I KZ09870
M6_-YDE6<4Q*<:QN1A=Y0=: IE2MQ\"FFH%9>"'2(3Y4?WK)3[\[L-1O*4]@V
M3]?1658UK>7>YA6F>NBKBD%[5&/]C//0!(*2!KS<RC7.&V?H9HC=$W'X2(+D
MQ AJS=)VEB559FS^L;\#\1G<5@2_6Y0Y,D7L-M0U&\HSS*1M4(68(?!M1HC3
M;(F4,393V./T'UC2J%??&9$?DH>;-$V5S!JE\4QD+RY+3%3E(AH">:XQ@]66
M 7-UK3'OSE28UU9OV<+>ZW=;[)H-Y3EN,:)O+4^+S$^2+(RDV'IBHU;LD"Q^
MAF5$C-TL4H)^!3_,O,U#>XT*+5D<?LT9!MRP"DE2O4%75WF'1=HE,/P?&!25
M54!<<BF@(Z(.T:R">J_7T:"T159MV*$L/[5&DGO?>-1M;]56LT4BR$6O5(*6
M?U"HG\>6M>W%N[-PS89R!&>!,EGK:)$0G0$=BO\0DB%I['Y2>Q%Q"Z%:A[*0
M2WMAV(CK@<@%/#G80V0I)YF[G4^; 92#6H@1,I"];<$#SC#=!?D_V@Q!?5QU
M3S6&]T5YGIOTE/.A8LQ\.<.(%557CGOWO:3.)Y6D1U-:#>?7*]6#Y _?W8M,
M@5DPG'%@JRF=P[%CO0'_ZTM^-YI-)VQ;UX>[FDSKLIK*=U(^DFH_<R(RGRNI
MHLDW'Y@UIX@@V1VK:S:4%V)-%:V6#M(]C4#]/#?%J1(OO&O34PM[YI2].K!Y
M>KJ%+Z/C#=M%:#'L26)'#&7P+4"M::1(+_,0)C61J9$ 0"/-*Q:LI8-23O;B
MK(.Z$8ZIG !'T(G9 C:PCNB<_R:3L+2UR2(Z3-P/.4UD^S7)>Z/I,WR+(N\6
M\4@L5Z74!+KHN.T.P#4;RD]P -Z8&5$>" ]&CJS[N3/%B. I2M)RU;B4EK<H
M-3-;S_'H@]"Y4GVGNM9G25E+F%&$)2T_8^3WLIE!YN,.$O:]#2<*-F(!XV*J
M/[_LY+0J$Y@>Z-PL.\MR6_XJV_%27;NA_ S[[3=R)?FJ=.R55+9YL9C:RFMO
M/^*Z1*SGVRQ=1[83BE?6(< Z75(>@8AL+"!MF..'RX=A#C:S0*%XK9B )QTB
MB*&.6HZ=U(">DCJ26>2'<:6DM5EM,CE-T"P('"K>"%G<4DU,S*=L6(]/,X2V
M@15,68UH(=L)Z.I[0;N2CZ&6$++54E[G[C1<LZ$<DX6K@0]8?TXV9'W8/Q3=
M"N6X.Q9,6\.,K.XFM]JOII/CO3ZC8H!4 ]VJX?2]E:-*96GW<[<F:N<=SH!=
M9$OMQX82QZL*=G&VRLDBGN=<HYUPS[$ZBN8M*%O(1B;TF"NL0]IX%\X%9(6)
M?Q0Y(UZU%DJ#ZQ2!W.6=7>.A_&V[WP<U8HYM1-[9$1H(K_QU539"Q*#"URK2
MMD FG0+"8TFS9 OZL4C>_0CGKZBP)54:W78LJ3P>D9@-M!-I84Y[2OW'F9.*
MBULBJGA)-;ACL2&YGT1DK^-7WED=J$_4"#H54>IC BBY4B4/?D+%C5.;:R<\
MH719(".<,J)'1-Q']*.E9E3#26):+LJ-MN7UAL2%5&N:R4E%<BUG1I=(Y$\G
M>H+@-WYAOF8CJ1-3YN0^E G/876(/Z 7819*-E9!;1WAI676")?)]M'6-7:E
M1_N!:?I1/Z8M^>3\3C@+MVB>RYSHT&RD#3HQU7+*L I%+=QE7;H6Z=E>F*YR
M#G>VJ?T-WQ->5O?I* 2L4 BGAS(Z'BECR01]XF;NI07OX5N\XR22E&AD8M6Y
MWWD\W(Y6)MX)UV]H*/^7A6NN%3YE+>L,=5QV:O@L[IJ&;DL+P!]8U0;>D%'T
M9^A<N?+II,6:.JL\?YICM!XJ+!#DR.>8T($V7MS9?EEEY9ML46(-_ "Z_G]L
M.5>1BAH84%:@SDZWM45V6W7S4*X:ICF QM@"V_[+H^@UD;#4#_$]4L%EA^6^
M4BSWP0[+_<=A1M\T;M>B0W=0KVLARE^]_ATTVQ-,9'[Q^LU1R+4N3(#XGZE2
M?25*%EW?Y'*E7V(H!U=,+B1$*NB/ (WJ.:K>F4=:!0I9DK(Z30H.D3>J@F[R
MVC#;#ZOJO \\5G#Z-?G1PR^$>X>X@@IB*R*BJE#A^BH[Y8JG]RONDZO>\I-D
M#[H>6,#6JGW&%F;'%A7 )JU_.1/N3%"UR3?0P-LH_@[J.948.RYF&.HL&L_F
MG6'@D Q)<C$3F(IJ(7G,.@G,S3O+@A#  O>C%QV2\K#.'@PI[F*]>YWH#@KW
M+AD7N&4UUQ5W<AD+]-VRZ-LB Y4?=1SPS+"+11L#DP"L<V).=_X<=""1YF/M
M7.\5X]$Y!6NUE$ <%=@ 6_<X?;;&@/@LNW:1CWZ+I9Q/"<82X_K/N0(<6"G"
M.Q&=E>P\@=7,#49SW2K8RHK$ZC^TJA,APJ.6T*F#O@%IDC^E=R6Y3A7\ZX/'
MV-B=0:I\1)1-Y'0B5QHL3AT5R9+S$1*>#\-[2>?4%9()R.6I%3=_>YM96X-T
M9X]PC'FB[-"]1 K8[]2\>\PN@2L#$<R^KK9XA/ 8U3PDL#';7$JD8 P)^T N
M%XS.&Y;/TB1Z@,B'S>Z5>E:!^4J>NS=M;J*#^\FM@[N3V9YU8[MXJ(V?'G)E
MG8,?[]WGDH!,0K@W6 O-'TQEEKJ8]A"0+TJ*M WUO"8,D.-CPQU D*!*JQ?4
M@OZF<BPP\W.&_?XJ9+/B%TP*-WE?Q8J^<C%\DVZ4:>]&P=CDL,"EDA_%VMLD
ML8UA8D',(E5"6'2OY@8#-,)BG9HE,=THFS7B63J<UG]:IDF]>&0#L!2NCVV(
M%IY-X8^L1G)C+A(A3,?TCZQ 7'IV*O_4K<W>26F3\YE\-[@$;V,7SN5=FR?G
MC_!).*V9##HK$*VY9JY"^ZZR"+LM5+E:ED@(0M$=VLZ\>)6*3;E5^:5\;J2]
M?KW0\<@O&$JDTT'O/;IG+OZ%H@M.M1 ^D[3T/%L>+#HUJ"6B3SI:DN>/BFV(
M&+$5EE@*P'O]V/CPRH8+RRH MI6<E1E'_U 0E>VTB3NW" 8?:M]E;:E1K8/.
MNN3&(])*9DP?/$^R7 J_8CR#"SPV)9(K\6U*A8XZE_9.'EVSH< %V)5'K-=B
MV:3#^3S+L7+6L'CBPCM>I@F=%W(4:V!MQALM)D.Y@/.VR%9Q] XO>BQA@UP<
ML",K&&OL78]R@HCHFEA*L]I8I$A$)7.E%D]5SK-&-)-,,PMR$1KV7S,WI% >
M#"O+XU%J3<*.KCP;5OJM?HRP=6BI]A)ONKV)K88'>A4%.OD;DEO(AC:0UN72
M@[1.@ \8QBCEUAF#^T.I;:/R7):!J@B5#1<H5M4GMK_EE9 ?<+ 2EFBZMA%,
M)_[.L]JC^>?%<&/2D0O8'2',82=FR0IC&,KOK9N "&H-0H@D$*M#)$I]&2-_
M:C&4K,WCG,Y003]X\#^6]E05]!)?Y0"FJ('7T2EG[<%2<7LV'$O-2-3%KUGF
M*763LK+I"_!?Y 9FX/82L4-40H^JWL'WI&N2+!]:KR'V5<_FDZW7JT'5W;$[
M$7O-AC))NR+V.=8+X=T-R^Q*4 P*V8WP!C!_4>:A+"2=*Y&_'<$Y_9I*=F6%
M6BLD3]AT[*+6$/#&Y;C@F#O-9;>AKME0)J:[H11*,+R%!BJ^U&*"V](I56,_
MZI54B6V!":VLAU*9M'5;=6659%0N;I6L&;O2K[WB:?&H95O0/5;^9L</_(QP
M&AEKD.1<GV4KQF9 BQ.KI*,)G*Q6)LGW8BEYAU!-P7"X-QE]3TP."N\-X0O,
MYN9)S:%3M#L(UVPHDWGW(%BB#MJ$6TQKNZC1E/(T$*T8#U9R0H<3?D:H7[7(
MV8&#Y2ER<XJ>?/)6DH UE(\R8"$%0A7W&YTEA8,&2+98D<AQ9,"P+]>&K4U0
M /NN0/P\>!A%?._II4&5)]8L<]&ZN^WZY3/_L&(_'K%F'WVZ8I\07(2OJP":
MRV5 :H+MD?!H)!N&J^>&4Q1[;H7.RD6?LG#J^),)4WQ9[(/*8JJOTQ9RN<;1
MG*IF05?2K)[E98TO\!V"V9GGSA_T5PPJC1UXT"PG$P+WJ;K^T7-()23P22XQ
M.@BIQ$JZXF:EN 4;&JC/FNJ/[<R/:PY+#U]FKWZN>9+&QJ/.5HD_::_T*I!1
M7==<BV:SB*$"2*2"2?(6@:==0V1X22A(30A>KUZTDNJR*CJ6#X5XFS><C4&#
MPF<X\KLQ7"!"#R&7BZ78%\%IT^W'\A(R;^-.((GKB:TM*Y_-+Q =']\+>K'M
MC.>Y4"Z-]79+C\OO[FWYA20?R/QAX- MO*PNC &3$IR_9CRR#ANI>KRM_4LT
M3V:WS(+-55_E\.E$BQSB'L!9@'=A&F)9R66H2>_#+MAHR,GDR:=+_3Z:3%T%
M[+F+>4BI8DQ]:QHNE\W%I<0IVHT#;F"/CB;J$#MZK7468=PNR)((W/+H-29=
MU":?[^TIGWWI\0.DP0GB$R.A-A0JAC,P8@V X9\(TCS5[WD!\*_B-+%R2![;
MG&#R-;75SUK:8[MR>0D XX\[K.*58A7O_I=A%7=FVQ\TVTZWFVTOR8>^V6Y3
M;P3_SL_>N(0%APT$KQN/R [<C'@8ZEQ0:0V=!L:E<_@E<[?:#4/=H)L5OUPF
M3<,V45;7+04%.#-D@TGDX8ZFR!J9I$B1(#8;9Y[ZM^J$,6QT8]!/;:;*$C8!
ME:/E/-TBI>K)[ W!EO;BJ"UR):ZCBKT*@.!D08^JHZV:#E)EP$ G36-:L>?1
M#0-]VA(F%7T8"^JY#%ND,H%[<I4U'#'Q1\%T)6JK3EOJQ5D&.Q2G'EY W<NJ
M6;M4<B!-ODC0(O4O;-"4D)LO7PMID8WB^J&"KBMU7DJ)7[LK1%O@.>%1H@Z-
MNVZ%R@8<AFP??:W'3V)>;/'H1M,$5"HJ_1M'IQ5LOZ@PIW!@V::#3MV6+-5Y
MFT=+,"XY^*UZE[J7OPYSYTX.;I&#BR$YB+ ./$98YP^TO$U1 >5QR-<^^Q 2
M8<TS+'1):C,;+HP2NN !5),YB$KNX,Q0]6DX-BR(:C_!UR,6(>8ME!&";\,L
M(.@]<J#4,=5YU9PEC*3-4;\F\A,JSX2"*A9".2WV+0T\1)=-: BH9$148):B
MD;6'HPQ%K"<ZE8_%*V#,8#D*C_B:?!?-I4.&DP2&0*$\0OZKE( S-)4Y2*/Q
M2_VQ5CNN,]@G2=43%K:*<;TG)M">Y\U@0-\$3=.D)OLA\5%CW-?8%TQY]M[D
M"N.@Q_?"F-"0$#[-SCC26[,O@^$F7&>]TU^7HS4>O2H;G#V4HJE&85&'.RW)
MLZ]9B]&%&WS@1J4*P8QM(Z2I(SV5FP![3V\&JX_3U]!OR.'W)%<4$(,R7>'Z
M6$JT,G$/_FH.C36<%\M1.;ZL92OBL&P9X\ N[6X]L49ID>SE-91WW"F"_=53
M-'=2>HN4SKI2^K+ZZ9&-GZ7)$@P0^".G1V.?%">V7%8U.HD+_ 2>2W*"HD[4
M.<[HO/'(P?/4Z224WLD2"[L.1N)JTX"BPB*JCW.+ I@;]%M/ 8,-ZUKZ1NH>
M]X6J9M=(4G%AU(]O@([F*\J6%12[37_-AC)YU]WT I;<N.D=NCL6CR/M4%!8
MVQ5O-26-U1K4<Y>4<&^2[DWNT>UW<!__OJNP[/'H(W#9NVUTS88R>=_=1F_E
MNL;E>\;W\V8PG=[M0BYKS1KOWE6E-7$4")(>+WD$/2:&,@@'6%W&TI(,FOM;
M? SQH)-A2,?B6O Z ]03F0(< :J[IV691F3JL4CWH1M3DZ.?>F#X&D!$D9LH
MM@$5J7+%T211^Z:LV2BL3@^8EY03]U1A<J6'I%TAV#ATDM"4)N@R\+LNL,:2
MQW#F=5L7]1Q5V[8 :P*,V'A "Q[0^)C4456\A N?XWHR\ACC4DA P[!P3WF\
MB*M_)T6N53KA7<[6[)9@>6UCJ)RT^588*=0AI7?+#TH#Y,@N2DN,\E93QWS%
MG@T1RZBE""+F<$&$*>SP:DD>,+?KN]19Z@S[..8L[!@3#KD2Q18[S^%T20:@
M9G##D[RA !YV /\;' &Y&5D2,BDIB]99N7(Q/]?+CKB,K5CT%=LAQR6[ X>$
MYT;/:HS$D\CUG=0./8S%8V7I'L1]!Z>DFFWQO8%6ZB6<=/A,!A14A?0H4!+N
MD*3I>6]]QL .Z&" 0##"]$3_I^(Q]3]"!PCB98RP26F2E_$R0:@OF1?TYTYJ
M()/^P6%8<@ICA]" KV57H'070BF+&Z_*F@*=DEVRF<-PHX=CHA':@.6\3O".
M"N8,.VV5-TIV/LO*W [(:G_?3Z:?DH6W'[TJB05+,K'Q$O79M,BL"3>[W>>4
MQQI2-I9#[IT+SNO7N2IV%\7@0.[Q17$XS+*EJ?U# 1."J.@Y\%FZ0NA";).<
M6-*33I1FM4]L1L"A =TO5M-79:B <H*8@A=$^FB%<SVD<3H+?3@HM1_][OL
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M\G4<PJ)?!Q@=, Q_M1[7+B!Z<[4SA)</9'SY43?;&;^."KI3Z:A6&REED:Q
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MZJ3<?OKZ^3_PZKG]\\DO+Y_\?U!+ P04    " !ZB4I6I,;TKM\A  !HP@
M"@   &5X,3 M,BYH=&WM/6E3'$>6WSNB_T.N8L<!$R4$.NRU8!2! %G,(E
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MK#58@_EL28$D.V&>%C);"$>1SL"P#-2HS$&1SW,U,S!T!+^ 8@^LN044:*#
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MYJ]Q(DD'W%6_8 T$//[_%J[I5L@UIGORYFDCA.(V<E==+N< P7X&HBS<5:=
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MAZ#.76J&3R=%EL;;P0'( 6*Q#-7T#>:EJY>M93PW(/] F0TP5L4:ZY@%!HA
M"9.328)VH?Q*7S:AW/T>8[E%IE=F[_=@Z<SH/*/:1T>(T)5RQ*RQ-FB:RWQ?
M.BI (+)BRR?$C\%)D@:JSF0IJGYOJGZMI0".; J@.U\-=O#"G4)%,4JK4K.$
M1%A*P8Y<;XM!_:&88NU!N!F!OQ?]GI\@"[-I<5<DF.5"$X77+1(T@"V^:9Z6
M,2:VNLPI,F&M X?6R3YLW/"CV$R+W2<;T:93W,\K\,/P0\C4<1 6G&WQY*F?
M;=$9GFN"UM-^M;K%/.R3EQ-M9<DR:9$#1H(?="J77%&#&WQSY" #GA%S.J=-
M$L2OR/V92?ZHI"+9G^BEK7XO]N'+R*N'#^R@EWY!QYS]$6YUA^G:]]J+&<R%
MB]#&,6!1855SSRB?I7/65*JK0P):5SQ'KH8-!,5#C.&,P3UXFC:L]F+=.ND<
ME!^*\,!=5REC'=SI&Z#N2R-7815PPA#6)D?XEQRE7SZB[.8@_UX7Y%]!D'^O
M"_)_[>+C*6=FG>D9<'ZT]06^#ZSW)Y5AN@]ZU$#JN[@"V5^<MW=,_#01?N<<
M^)<VD1<_',Q1G3IGY<\EY@TJ6S"SK\[9,3#GU^;+ '-5?(X4[;M>\8>"R<9,
M,M]S3%XBBAIR@#/00!OIU(0@,/+W55* Y_ S9-:0EU<0TT(G;+^@#,9\'U-H
M+Y!*X<J1=A*WWZN3F+JR>5,:<8N7)B]($Z[*5WAJ+6JS*N'Z !GQL '(\H3O
M1_F ]U&5#%3MB4$BCJ_ML6#/U)_+<] ?])0AYR[32VZ7V@FX=-;'O@Y[O:/N
MZS)G*G=5$BT3KXJN0 '+A.(F"JM7!.ELEF9%F:!"3%[O]P&ZG"NF2A4LKO"1
M^1QO)O]SEOA@@F:&O3/'TC'8TA2;&?N'!8RP3QEIIFE$FJMMN,&/2XSL(G"!
MJF*$Z""78@9N2E2Z!HSK&6'2,WUE]'P % Z+G.B!>.Q_*T$#!FZ D&*B=K87
M?$!K8])^4*<)42!#?M$8^?:G[8V*\Y39@0NC+V\5SX9#"_5=&UE8-F8;=B?T
MGDR#<H)J (CV(R@12]9.<"PS30,"%?N2:M642:[CH$)L7!.6XK,P@AF*BF09
M/V:5'=3JB%A:X1.!!VO!5U/*4G[M06>,">6WLD-HNQ::1:&4Z7A!'"!I.HHI
M[ N, 0^0O0LQ&Y?L+J?\X$K'N]++]CX^D!8%I*'Z,'#RVQ9E8Y]>K2J/8)+J
M@IS!FLR<O!G45T YD<\@"9^A8=XA1K_,&&PDDK<F0:@)9TQ$6OZ&^Z5"E5UT
MOP@7%7.98BP*O\EJ^FVS0(QWQJM\!AD7%^*J<=R.!]R3:9#OJY7 B(WCH;29
M[Y0^T=0V+;W +VF,1T(%$SCL0&)4&@H]V:BZ,GDIQ/<$EZ6B(B-6TR2Q@F1&
M#AX@5]0;B>S:CE<;3=6T5PEBRG4@KL:FL$ )QLN%R_&I-=#C@[&*5CZ19VQ0
M7]11,6<>2(MMYQ]M*8HE>=, U BR@"-&-A"TG)^ORB)%]2KDT /Z/[$R%E 2
MX8Y<;NHU&$K/6<RB"4.;UL<J0_"<J_:7]K':"^'UE-N8.GA$,Q'203G\&.=G
M)^Z'0,AW8=X?CUTDD2%LJ.PC7*:MP$2@O,HI(QVG\P:V.=246EO5?V%8FE\"
MI@)Z6?J>$UQ2"CLUP=)$^\2&"U=_#2F,V#MR\(TGF\$4IC;)V?KV,_N1D3IM
MP%6?:CV1?.:LJ,EKM6]LY(Q**J#:EHX[DEV?S7X\;J.1R&BDK5A;TN/X2GOQ
MH<$U\#2-"$IM\T(O)+:MN;Z.+4S#BCLA(S=MF8!K*'2N0><(-G;WKJ=1/F:W
MI,_@!O+L]WSZ)!% VBZ+@9M#AM5,_9BA%S1C3YU-326\IO5T-8?:[S7D%^(V
M+4P@8S080V$R"PR+U3SGM<A#:V%%Z#XSHQ*?T9VV]=G?[:=M!);C5+-HP+CL
MK4]>Q;PU49;XNBR+W=O;T)O(TIV&$'&-)[0X@3RWZ!A95S$I'QEGLL S72U)
MD&S+]%[I402[D>)?F!N ^3J=P7=/IG$KL(,*!*I"['29[*SSA&N_$/RHD<\I
M/J-F=@7^1 ^@6D&6NTNLH)!<&((JM:O%':=:DTWVK:TXBN9T;O?_7+!;ASI#
MKYN8X"_ 5HLD9"-1SK%?PD<*]Z!9S_6)/=Y",G:9MU"1'^%M6$O72P1T$C]6
M>6%+5?D5:9AZX36WT)-=_=-&Y5O?%EWJN-#O(1'/9&E@3(DM2DC:N:Q1&[+:
MQZ=4B'/_KFNJMY*CAOV8WA1@))&753E/@XT]627AZ S^#=G_Z2UB#0+9G&S%
MV:OR3)*?64S(')TILX1")Z.U33+I!-Z[LPE;M<AM HR_81+?R5WU%D3&)]Z*
MV@>Z],>9JI)&%0'K70TRR0U0]3*5L+@?K=\BRAW7GN:*NC;""=I?F>$'@FC1
M$(BFZ]!C],&BCQ:/RTQ*P&!6''&]MDU5(05^(JZQZ?35!L05*\C)?.UYJM?]
M;7AF:Q6_&Q[Y?J]RP;LC^ Q6C5@R07*<!*_6OTD? ZJ:C6JHJB!6K*A[:C2Y
M*F9<L(6("I.IBC1;>*O>[S&=/@@V?S/\ZDD'OUH!_.I)![_ZVC63[\1;+!8P
M*QQ '16N?HE_UL3-IYO+GJ5#V:<(1BC2?F]D&D$TP;WX7WGN#(I[C,L,"Y6@
MB8>"U(J\A,N %NQM:!%LL9;D4W2ID(3+;'AC G*.\ (:'8EX'*3<+FOK*)90
M# 6))O]=1C%>? R546.L?;.ICSAN;)00L0VS@NKRR9IYOAP81?6I@EZTAFOK
M>_,@V/Z7>(;^S&?H!ZHUAYMBJ\Y6S066HB5^%5GL%=.D7>N$X*0TT1>G 9=G
M([6?JMM*Q5HI9-OO20\:#^K";V1M37<=9M87RV >0.S %DUO]ZOFS5+8HO!R
M0117#%FN C40$Q %@$])2^A0Q5Q?UM9).0Y1X1A3J@['B:O/>64)7*-9&_MN
M#W7(_8]<UH0'?(HR"]S*4RJX*&;:PLYH@VJW]WO3E"L')*@DV]G0.LI#]$V/
MR1OU2O+-+NU^?5$/ 0Y9=.DREMN54V!('1M9G"3:CL:EW,,FA.$F*E58%=GU
M]?*<(KN[$G;H"&1]CGH$,\,KJW3[*F-(SB]G#L7L^&YCBXR3-G5]%.UF;E!1
MJQ)?3^B4-UC-CGB.K\4."+\0AJ1E&E=G'K.A,4*;CU5(IC:A^1BNMQ2R$UU,
M:A(LE5*RDT0AW38Y C5T]+DVG_XR 1 >N>$K<AXM3'2K^XTLCL1K&(-P8?)(
M%>H#L3+D=U04(PE^3,@1>%Z0!([0A9#EU*4@5/E$S*F12MYS<E\^,1ZC#"<:
MFW6*$$=,)'Y!51R!G-&2B3@C&K.EX3DPU+#D/@85HB:.P4#?PE:)_ (RMNRD
M7&4UO[)6TPO&)4(HZ##*TO><DHC=%F<(F8QTC#T-VMHTJ*EM14.%4'24+SM\
M<Y=-096>U7)CT "6E\.]+<[&3]D.OT\#%A"2-7C!.=;^^N$X9 $3&,9URX;W
M\,"77+CX3MN<0J:(PX()"2R0I^92\-MH#$;Q\5G9)'&> 844R;=]C?3\Y$%X
M*XOE)-H'44,">(/VBMJ3NX#4/&HS:_?$Q5#IP:PXU$QN=96:B$-MV25[$-IH
M%.,)6+V&&'95!%RZ(=&;))+7F<^?8= '"!+WC(^@U1:Y3L&KE^*ZSJ;6D=<T
MJ+)8Q*(FP\CV<FQ10O@9C=!01QMK<JW\A5TK-E(J(.4#&^HA#.O0"_74>K4V
MP2&8Z);84C4UT)37ZG/W6S!H'-S>\:E^[V,%*/P.V;6'-?O++SP";V-9[5$M
MVTR; H/7]YMLY XVW+4U?EQ+ FS-%:Q=80LAP9UG)3+]W:=/2=J7\:6JM^=N
MYB'28CVYJ3=J_8[ZBG&3)84),QBCSLV'8.-;"UD#;9H#;4O0M5H2L/.L"'ST
MX_W0I,-<X=*)YRJ7]?&4E0D8FUOYG%0##F%7]3GK=4V0$CHVLJX&SSO,1PXB
M?*&70.[[9KU@;@LLJ[7;I% 7YUI5$ 0,Z%((&$.S9- .+"'D"(0$!K/!M8ZH
M"!F==&Z'1@".#6)W0\)Y;/KOZ.AG7?0C'<)/2 .5Q+Y7C#)\0TXLSK' ?DL2
M0I,BTW7NVPJ>Y>@0%E[,FL$@SAY%]+ND &*) A8?[#M;KIE3$R\U44*F7K/>
M82[LM=%>LX(:5Z-IU/4?U-#% KFLO'I<A@L7Q'E#VL=%X4;E#F9UXBB):2SF
M;T#P7HVI5=4W55 1P3NN\#,9YR"V[!>$,[%K=/-@&N FF0")%"J][.%\6,Y(
MD;#&^H%4NL4"UM&JK4M7=(#^]1Y\Z15^6 5=8?NOTSB[75I?IE B7B\J2LVE
M0'RO4TIE;^-%E0"V7(0#L;;Z"G4]/KRQFB]CTL0C<0O&[C.!>L(&,X)ZS>F:
MIZ4!NEA2\ZE&XR4B)USSOSPO,X(4-#S6-;=(X')1/ZVO?>5E=_;(4O<$.VTK
M/)Q\J_% =Q4(LCHS3.>N23554?;#06F"?0)HZQ*L4 ^T8;FPCRQ!W@X&ALW'
MEO825>$4% *V7J+T0+L63BCRNRZ-K!'&U>GJYA'.F09[4YV7FA/,$AF+D'X/
ML\9%&%30&*I)D0?PH,R+B%T*<OR&K>3]0BN0DN_=1&ISN-'DJ_"-MY[*@V"!
M-T,/GW;0PQ5 #Y]VT,.O7&J/:C6Y6<8TQ(_G_2=VSFUHO:9!%2Y/TBPU)[X0
M/OT6+97QH2P@8R-=Z)M>,8PQL7?:$]2?)CT)D$X"IV*BVGH3;5U2K#VW")S"
M,-98XB1F'40,0]>'-6,H^)6*K2B[1-LN(20CE9(I8T7R?Y1&:/[XL9,EU6,@
MU<NK2GK]GM.2#.@5TB?6ACYO-J JD5%#,_DMW<5!6;GK&;442R-6:J,AZ$\0
MS_BNUMT9U/=FT+H^3<0H"];/4R[X;@_00RBZL?M$_/O86%T<KZZRHTMV8C0'
M$$5+MAVQC3%V6!*,&H8%!\(]IM*9HNZ2;?/P]7L)#@%NHW@N/ ?AR'BO.PFH
M6;J&.=2 RL;%*1+)XZ,LJ @><M<D]F"ZJJ^>IJ2BZ$$V,L(IF*0.$ELC&M,G
M%]0&&WNJD$,I5F8*M,21/TQFXI+1?MOI9IJG-$>@%C$SD"C"A40MI@_]G@&C
M4[L<*NS+HE4XX4+)H+>$3(.5QTE:" F@EZB[3&QE2^"W6"8(/7C3DIJMJ6HX
ME:=:%P57HT:!-#54.AI+8EN;AAHQ6U%66Q%>!HZ#T-+@F9*#H*KU1":-&_(S
MMDT[1(L-[G5?;'C ?3L=&B>5YI(>&6Q!108K"E(QM)27;!.Q6*C086U[N ZE
MM[R8A4-;4_NLC*MPVL$4" /K('D$$!SDA")EU.U$)X2TX</,08!(A]Q4C72%
M.4/](P?0]\90I?.9!$N5R?H,+#@_C,L<#;>4FPTU-I3*F>#7@CJ0EG"_EM$E
M40+*1Y2-"0>MV?^7N/:%:0FB4: EOX(ND4<FM)/J'(7KY#I2=ND5]SVWT:7V
M6)(]4J(8H@)$%>A8;6RT5F]R!$XB,9G4#VP4U1N0QH2Z'O5EX6J2U,FI(XUU
MD89D?Y]09@>#G0XLPEU$$Z?QX\\#KK**>U>E"=$VNLX'U+RH-5JY(>%M@2UN
M5B3G=2=BCN,%-A$08;BN,/H4$[2R!+VGG9?)8O(Y9,EP&6H+\%I'PP_D83*P
M/BKC#.09^BOE(=QM&B&5*J2+M/N%O(#C-([3>?YP:VM73A[?J=-T^GSR9&L^
MGVM]0X_(M^%Y@&[_@A9?T2/K*:G\0Y\\X#__\0Z7_.)H!2-\NK?2(5Y@A1@<
MD_65/U_M<)_MK'2X1]DVC^EO*:A1;]49!8X#?\SDG[LG='5/B>DK&-8O?_K3
MG_[5D44WK(XL[M/ZW]-A@0HLE/'CRXXZNF%];%@=77S683DE5; BSX-[-\2W
M9JQ_.!KP6(Z3<+LCEVY8]6'M/?F6Q_':C(M)<'"E$VS0<%YB#Z>G.SL=Q73#
MJ@\+KN1Q8/!B$)S\C Z5G=W.W.V&M:S DL_]?V.00]-H.TRGU^NR@EUZ2&[,
M>QXP2*730]7RRQ6CR6WHDV,J4W)<2Z4E\6_3'0.I[R5Y[9+H9:9\%?R?@X54
M'$T"JQCR&QM;;4E\W_U>E2)&F=<.#%NYP*<JG)C$*P_J"HXQP@9C..,R;G&:
M;]-*5#<29E;2C%*N-#F0JF7]'J6X<52181'V*94;7[SS4V7B+DBTKB"1%.([
M*(HT2W25#?I:Z[P%$F.!W)FDM=:@#?\%HL$"QINH!L8M#)K !0D[#UR$2H46
M.">E':C>16Y+YTIU%WX"AS=OP.8,)$L[T]B?DI \!%VHCHPM&>..6Y(F6TO7
M8P'V(I<6(@2F4++,N:QS,$94?ICFTF=-?YCII"L*L,;S($7UOB=@(V[E6S5O
MC:I;RA/("L%Z5!VEPQC&,0$$BZQT)%HG<G=8JFQJZ9*.!2ZJ4T-EJKDB")X,
M_'@%BQ-1RW@2)5Z3/M>0AOMR2*D!*L^7A%X*F" XL:Z?-RXLM$9X%WZU0%6E
MP";!\@O)=CZ" <X1+62+,5<Y N$D-2Q5,->@WC[O0=#WS7C]9QU>?P5X_6<=
M7O^K9\E2C.,4<>E#45;;6#)VBDM]Z*ST(@7.#/IQ0>EPT6/4)*JF%Q['=JH$
MEHJHM S4;HF!FZ(L-+-"E/\(%73"8*2+.<*\KP%.Y25JO#I"% Z"\"B?-\7Y
M4.-WFTM7U2J\X7DX.Q0,M?Z*-@, S &LS&_;'579X#71E4AFH-.!Y :+ N04
M@6@0S!6H[!&)-JYW1&+"-OG SF "_*%2LE4J6H7Z:5;?8PAHY@$TE8&U%22J
MK^+9Y ,:BPPEJT;B#X1PI@:3+LK+2?$@9,N7>%#W=FS2<DF*!"+36U4G"S8E
M98;S,+!? =61RZQ=R?</ L8MCVV^N]5;L!BV]+/.S"5"8KF?01Q3E25!-J>7
MVDNGK(XQO<_6Q2:$O2$5#8?'MK;3M%J@^S)^"]2M+&6VW\L,Z95S*YOCY60!
M;]0=M:Z+6G=M#@CKY6^T0G57*-9^.Y%OK1Y=9?0 P8"*)!G)U'.+G2@)=R$-
M:DV2JMVGVBQ(ZN3XF9L<1(HB0/C HJV9B3-XT;_5J>=MB4L#OU>/5(G);K1R
M.\K[#(,^/NGW?CJ^.!F>GP<_O1F>#4]?MPEU(BNL(LP0ZXEE39%B8N)6+B8#
M2:E&:95_O^(][""I_WTLY78+]KM7^N8HQ>$IKNO)7Q_M??(BKC1@?OQZ6 7,
M3P[7$C#_ZC9BG6"6VY+*3$4H3YVO@[P<*P$4KQB1_9&!KA3X_&IQ,S#[8_XA
M?N2G(<U7.X/]XY>/\\>"WD8IF@3GX00TIA'V]CE>"^YNK>=_G< "=*'=NU$Q
M5?!0/-+HR.)S;< %1JSN'UWP:AU.C![S>(9L>(..>\H5<[\Z(NETAP>^V"W'
MX/3=Q?'IR7#XO-N CMJO5T#OAUA:]>#6JA+?E1I\E&W7$QD[/;C3@Z]+<OV<
M6$Z.S7]9GMG5C_F7<QNKZ?<0$H .]I,TV9+:7M0C">N*2<\<YS7_UY<US=\!
M7/FV ZZL +CR[5<%7+EK,MY_Y2;TZN67=0)AZ/L_OAS^\\WQJ^.+?N^ H?MW
M.XLO,OIV)TO_^O3LAW[O]'5P<GIQ?#@,X"\VM8+A/X=GA\?GPVXO5A[ZNTB?
M]WN2-$GYDK6V.Z[O$#?:Z=;^[@>]L2M%;PE>+) L##UC<3[L"DWM!5RIU7^[
M?ZZKMEIO(57;7NZ597>W5O:;$D-J'6R:VA7W4(UJ^#?[$AL3]^<040<H1<_S
M1@W_#H*]'?POW46Y,!QL)W"@U*ER7>X;K09-PETXX;E59]^1CM.'46?\O@]Z
M8P^H]9UT0&483:'><]H&=:.'7=O@UJ->+?A1^F'S8?29?_@8B4\:\%UG&:ZD
M%-;*!_D+CY+_R^/[UXJ&?,=$;:-\L9IC'J&T!F9&6V\_+-WP[)GV.A K[D'L
M^@NW=B*6WAAJP>=_T90./(QZ'^"NTL>#&-;GYLP=L7SN8?W"H_"YX$/G?PJ$
M2299WN.J@[DT)PHPX8,]D\+J.I;VD(;5L;3[N"L=2_-9FL^M*L^ LJ;_*$O?
M@U&!A;]S9'.HM5%)?FM?BU<@H!;8>9B9$6?_V&R+[S:BS>M< QWE/HAA=6SN
M/NY*Q^8^@<TENE@Q:P,3MR/8AS"LCKO=QUWIN-O'N5LMO+/A>%V.G[?@\JV<
MV]/6V=WF[^)WUZ2#W6GINBZJ\@2C*K'& !]7)E)!B*>?&AER-[+J8UXU^*$:
M0%CSAVE%G!8))LW+_OH1.<Y(]HKAT85 )5B?P7HP^CV*ICV,<,U*!GU'S1K_
M?8M_OM9-:*TY<%>("(Q\RP'R2D+87D=71@5<<.QR4E"W-0,G9X,+V60J?$_5
M[!(JW\5MUZB,A"OR)9Y"[QQNVN^XR1$UTN.JE _CT-U]C/1W!T)7$?-\LMK.
M.G<1\>0AWA_0T:U9'$V\&_?7.NZ#HDB>\ZB^Q.%?Z/@CH_>'OZJ^9'?-CAZ,
M$=!A=VH#7G&'N+N08\_NF1RSF:#WF0G=Q/O;>="#.>#_I:%A\TO\- Z:3".]
M9L4;]LOPP\2,3-'O'?S>1*=[A3#_'6E-W[V0*>;/@[<J+[HLIQ5D.7WW>[.<
MOM("NG<_OL>O3H]^1N[Z^,W%#V]?_C]02P,$%     @ >HE*5OU=@]:5#0
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M-I*97#*W.0$D*9@6 @3?4UW[]E$XV\E\-H S(YPPI?BX3<6(XSJ;8G<P)CR
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M'('KK!.8FI'@I\6$*BDQE\GUICV$ ?<YX(6""\2$E* C@]#J?4>=_2J#9\K
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M:^!]2P7H )L"J&HC%6! 6.=RB -G1XC'_"& 70XB#/I,Y82@@:1%"N-0]:L
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M7 ?\-2& W=EK^S- D!D6!,M)%$94IYM/6$-98Q4A>JN]L! XB-%JE,.&,OU
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M\:RRA8E7#TK&E+KG.GI[_@$R+& %T-@T(?,]B@G.'8FWEYOFK[_4]YG)_SJ
M]2]X7R)8#AJC)B3%$ )(<R?]MFN.)N]7C^ZMI6ZQQ1-=FO>VH>?P5 I0'!JH
M9KP3"LRC(E[O.B6!MLEG^^WF&_?#_=4#>^1_4$L! A0#%     @ >HE*5@G2
M3)P28   0R$"  H              ( !     &5X,3 M,2YH=&U02P$"% ,4
M    " !ZB4I6I,;TKM\A  !HP@  "@              @ $Z8   97@Q,"TR
M+FAT;5!+ 0(4 Q0    ( 'J)2E;.Z@S]BB@  )T? 0 *              "
M 4&"  !E>#$P+3,N:'1M4$L! A0#%     @ >HE*5OU=@]:5#0  PS@   H
M             ( !\ZH  &5X.3DM,2YH=&U02P$"% ,4    " !ZB4I6G1)5
MI> :  ">O   "P              @ &PN   9F]R;3@M:RYH=&U02P$"% ,4
M    " !ZB4I6H:K5F/L#  "Z#P  $0              @ &YTP  ;&9M9"TR
M,#(S,#(P.2YX<V102P$"% ,4    " !ZB4I62_%LX@@)  "M:   %0
M        @ 'CUP  ;&9M9"TR,#(S,#(P.5]D968N>&UL4$L! A0#%     @
M>HE*5O2XCIH%#   ;9   !4              ( !'N$  &QF;60M,C R,S R
M,#E?;&%B+GAM;%!+ 0(4 Q0    ( 'J)2E:T99\E4 @  $=C   5
M      "  5;M  !L9FUD+3(P,C,P,C Y7W!R92YX;6Q02P4&      D "0 A
) @  V?4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
